Podcasts about thermo fisher

Dr. Deb Muth 00:00:09 Hi there, how are you? Bob Miller 00:00:10 Excellent! Pedaling as fast as humanly possible, but doing okay. Dr. Deb Muth 00:00:14 Good, good. Well, I’m looking forward to our conversation today. This should be amazing. Bob Miller 00:00:20 Yeah, it should be a lot of fun. Dr. Deb Muth 00:00:22 Yeah, anything that’s off-limits for you in, our conversation? Bob Miller 00:00:28 No. Dr. Deb Muth 00:00:29 Okay, anything you want me to make sure we cover for you? Bob Miller 00:00:33 Well, I mean, is it okay if we put a little plug-in for our software? Dr. Deb Muth 00:00:35 Absolutely. Bob Miller 00:00:36 Yeah. Dr. Deb Muth 00:00:37 Absolutely. Bob Miller 00:00:36 Yeah. Dr. Deb Muth 00:00:37 Absolutely. Bob Miller 00:00:38 Hey, can we… can we do a screen share? Yes, we can. Yeah, because I want to show you some maps, and… Dr. Deb Muth 00:00:43 Okay. Things like that, yeah, so… Perfect. So just let me know when you want to do screen share. Bob Miller 00:00:48 Okay. Dr. Deb Muth 00:00:49 And yeah, feel free to plug your software wherever you want to. Bob Miller 00:00:53 Okay, well, good. Let me pull up a, a slide for that, and give me one second, I just want to shut the door to my office to get the noise down. Dr. Deb Muth 00:01:01 No worries. Bob Miller 00:01:16 And, how should I refer to you? Dr. Debb? Dr. Muth, what do you like? Dr. Deb Muth 00:01:18 Dr. Deb is great, or Deb, either way, I’m pretty informal, so… Bob Miller 00:01:22 Yeah, and… Bob is fine for me. Okay. Yeah. Yeah, there you go. Why people feel like they need this, son. Special name, it’s like, seriously. Dr. Deb Muth 00:01:33 Right? I agree. Bob Miller 00:01:35 When I work with my clients, it’s like, Dr. Millison, just, just bop, just, just bop. Dr. Deb Muth 00:01:41 Yep, that’s how I am, too. Just call me Deb, it’s good. Dr. Deb Muth 00:01:44 They feel a little awkward with that, you know? They’re not used to that, but… Bob Miller 00:01:48 Alright. And you’re a naturopath, medical doctor. Dr. Deb Muth 00:01:52 A nastropathic doctor and a nurse practitioner. Oh, nice. Yeah, so I got the best of both worlds, right? Bob Miller 00:01:58 Yeah, damn. Okay. Alright, so here we go… There we go. Alright, so I got that ready, and then I will do a, I will do a screen share. I think you’re gonna really, appreciate what we’ve come up with. We’ve come up with the concept of, Cellular CPR. Dr. Deb Muth 00:02:23 Oh, nice! Bob Miller 00:02:24 And that is, construct the cell membrane, Protect the cell membrane. And restore it if it’s damaged. Dr. Deb Muth 00:02:32 Love that. Bob Miller 00:02:34 I love that. Yeah, so that’s what we’re focusing on, and then how, You know, we want to get to the point that, you know, most people think of genetics, they think of, like, 23andMe or Ancestry. Dr. Deb Muth 00:02:44 Yeah. Bob Miller 00:02:45 And then you have the professional geneticists who are looking at, you know, odd things that could create a disease. We’re looking at functional genomics. Dr. Deb Muth 00:02:54 Which is so much better. Bob Miller 00:02:56 Yeah. Are you familiar with what we do here, or… Dr. Deb Muth 00:02:58 A little bit, a little bit. So, it’ll be new to me, too, so I’m excited. Bob Miller 00:03:03 And how much time do we have? Dr. Deb Muth 00:03:04 We have an hour, give or take a little bit on either side. Do you have a hard stop anywhere? Bob Miller 00:03:10 No, no, I put a, I moved my clients around, and I don’t have anybody till, 3.30, so we’re good. Okay. Dr. Deb Muth 00:03:16 Perfect. Alright. Bob Miller 00:03:18 It’s like we’re getting started early as well, so… Dr. Deb Muth 00:03:19 Yeah, we’re getting started a little bit early, so that’s good. Bob Miller 00:03:22 Yeah, I just got my office cleaned up, so… Dr. Deb Muth 00:03:23 Okay, good. All right, are you all set to get started? Bob Miller 00:03:28 I’m good to go, my friend. Dr. Deb Muth 00:03:29 I’m gonna just record a little intro and a little bit of a, hook for people, and then we’ll get started. I’ll ask you to kind of tell us a little bit about yourself, and then we’ll just take this conversation wherever it’s supposed to go. Bob Miller 00:03:39 Okay, you got it. Dr. Deb Muth 00:03:40 Alright, sounds good. So what if the reason you’re not healing isn’t your diet, your supplements, or your labs, but it’s actually your genes? Dr. Bob Miller is uncovering how genetic variants, when combined with modern toxins, explain why some of us stay sick no matter what we try. Today, we’re talking genetic pathways, detox blocks, and the new science every wellness warrior needs to know. Welcome back to Let’s Talk Wellness Now, the show where we uncover the root causes of chronic illness, exploring cutting-edge regenerative medicine, and empower you to heal from the inside out. I’m Dr. Deb, your medical detective, and today, our guest, Dr. Bob Miller, is a true pioneer in functional genomics. He’s a board-certified traditional naturopath and the founder of Neutrogenetic Research Institute. And he’s the leading groundbreaking research on how genetic variants influence chronic illness, inflammation, and detoxification. His work has been recognized on international stages, uncovering links between genetic expression and conditions like Lyme disease, mast cell activation, or MCAS, and mitochondrial dysfunction. I’m so excited to talk to Dr. Bob today. He is gonna reveal some things that even I don’t know about, so I’m excited to learn alongside of you guys. So… Dr. Bob, let’s get started. Tell us a little bit about yourself, and kind of how you got on this journey. Bob Miller 00:05:04 Well, that’s, that’s interesting. I was sort of like a mid-career coming to the natural health field, because in my early 30s, I found myself with a severe case of ulcerative colitis. Bob Miller 00:05:15 And I was in the hospital for 21 days. probably within hours of death, pleading to death. And they told me I’ve got one option, and that is cut out the colon and wear a bag. Didn’t sound like a lot of fun. Dr. Deb Muth 00:05:27 Not an option I would want. Bob Miller 00:05:29 So, you know, the medical folks wasn’t real happy with me, but I said, yeah, I’d like to explore some alternative things.Never thinking that I’d get into this field, and then I just, you know, worked with some herbalists and things that I found absolutely fascinating. So, that’s how I got into this around 30 years ago. And, haven’t looked back since, and just having a… having a blast as we now move into how our genetics impacts things. So, that’s what we’re gonna… that’s what we’re gonna talk about today. Dr. Deb Muth 00:05:58 I’m excited to talk about this genetic thing. When you started over 30 years ago, what kind of patience and problems first inspired you to dig deeper into that root cause healing and kind of get into the genetic piece of it? Bob Miller 00:06:10 Sure. Well, you know, as a… now, I’m in a part of the country called Lancaster County, Pennsylvania, where there’s a lot of Amish and Mennonite, and they gravitate towards these things.So, this is their first thing to do, and that doesn’t work, then they’ll go other routes. So, you know, back then, we just saw typical, you know, a little tired, constipation. You know, a little bit of fatigue, arthritis, those kind of things. But things have changed dramatically over the years, as people are now getting more chronically sick. You know, it’s worse than it’s ever been. And what we’re finding is the, the culprits Primarily is mold exposure and Lyme disease. When people get those two together, they’re just… it’s an inflammatory cascade that nobody can seem to unravel. So that’s where we spend a lot of our time. And we’re also spending a lot of time looking at mental health, like ADD, ADHD. And, we give… this year I’ll be speaking at three autism conferences. And we can dig into that a little bit as to why we think we’re seeing such a dramatic increase. And aside from autism, that used to be 1 out of 1,000, now it’s 1 out of 33, or 23. You know, we’re also seeing dramatic increases in ADD, ADHD. People are stressed out. And today, I think we’ll have the time to actually go through and show how environmental factors combine with genetics to cause that to happen. So we’ll… we should have a fun visit here today. And today, I think we’ll have the time to actually go through and show how environmental factors combine with genetics to cause that to happen. So we’ll… we should have a fun visit here today. Dr. Deb Muth 00:07:37 This should be a fun visit. We can cover lots of topics. I am so excited. So, you founded Nutri Genetic Research Institute in 2015. What did you hope to accomplish, and what kind of surprised you in your findings so far about that? Bob Miller 00:07:51 Well, you know, let’s back up at what, you know, genetics is used for. Everybody’s familiar with 23andMe and Ancestry that, you know, tells you where your ancestors came from. Then you have your professional geneticists. I mean, these are people with a degree in genetics. And they’ll look for, you know, very odd sort of things that are prone to relate to a disease. So there are disease-related genetics. Well, in functional, we don’t look at either of those. We look at For example, how you’re breaking down your fats and utilizing them. How you’re recycling your glutathione. How you might be handling your iron. And none of those are disease-causing on their own.And none of those are disease-causing on their own. But when they pile up on you, and then combine that with environmental factors, that’s when things start to go south on us. So, that’s what we’re doing, we’re looking at patterns. And our first foray into this was, we did studies on Lyme disease. And our first foray into this was, we did studies on Lyme disease. So, we looked at, like, I think 50 people with Lyme disease. We looked at their genome. So, we looked at, like, I think 50 people with Lyme disease. We looked at their genome. And we found patterns that were more evident in those with Lyme. Now, this doesn’t… these genetics don’t mean you get Lyme, it just means if you get Lyme, you react worse to it. And we found patterns that were more evident in those with Lyme. Now, this doesn’t… these genetics don’t mean you get Lyme, it just means if you get Lyme, you react worse to it. So, as you know, some people get Lyme, they go on a round of antibiotics, and they’re done. So, as you know, some people get Lyme, they go on a round of antibiotics, and they’re done. Others have a little more struggle, and then others are struggling terribly for years. So there’s an old adage of genetics loads the gun, environment pulls the trigger. Dr. Deb Muth 00:09:14 Yeah, that is so true, and I think when we’re talking about Lyme and mold and things like that, we forget sometimes that our genetics can predispose us to be more sensitive to those things, and if we have genetic pathways where we don’t clear things properly, it’s harder for us to get them out of the body. And then you add on that whole rain barrel effect that we’ve always used as a functional medicine term, right? If the barrel’s half full, you’re okay. If it’s full, and now it’s spilling over, it’s a bigger problem. Have you guys found, too, that some of these environmental things actually are changing the genetics of people, or how they’re processing their own genetics? Bob Miller 00:09:53 Well, let’s go back to, Genetics 101. But we’ll go back a little bit further. So, what an interesting mechanism, what a miracle the body is. Bob Miller 00:10:03 Fats, carbohydrates, proteins, drink water, breathe air, expose the sunlight, and somehow everything gets made. I mean, when you just step back and think about that, it’s like, It’s pretty darn amazing. Dr. Deb Muth 00:10:15 I always tell women, you know, the fact that we get pregnant and we have healthy pregnancies and births is a miracle, because if we had to try to control that, that wouldn’t work so well. Bob Miller 00:10:25 Right. Well, that’s another miracle. These microscopic sperm and egg, human being, 9 months later, it’s like. But even inside of us. We are making our hair, our skin, our nails, our blood vessels, our ATP, our energy, it’s all being created. Well, that gets created by enzymes. So, enzymes take one substance, combine it with something else, and make something new. Then another enzyme comes along and does the same thing. Your DNA is the instructions on how to make the enzymes. So, when we are conceived. If it’s a, if it’s a female, of course, it’s the XX, the two chromosomes. You know, we’ve… everybody’s seen those… the genetics that… Listed pair. So, if it’s a female, the father donated the X enzyme. And the mother has no choice but to give the eggs, so that’s female. If the father donates the Y, you have a male that’s in chromosome number 1. Then 2 through 23 is the rest of the instructions on how to make enzymes. So, what can happen? We can get what are called SNPs, single nucleotide polymorphisms. And SNPs just mean that the instructions to make the enzyme’s not quite as good. So, if one parent gives a SNP on the making of an enzyme, The enzyme’s fine. It works. But, general rule of thumb, It may only work at 70-80% of efficiency. Now, a good analogy is think of an 8-cylinder and a 6-cylinder car. If parents give you good information, that’s like having an 8-cylinder car. If one parent gives you that snip, it’s like having a 6-cylinder car. Now, is a 6-cylinder car a fine car? Sure. It’ll get you from point A to point B, but it’s just going to have the power of an 8-cylinder. Then if both parents give you a SNP on the same enzyme, it may be 30-40%, and that’s like having a 4-cylinder car. Sits in the driveway, looks the same, puts gas in it, everything. But if you’ve got a 4-cylinder car. Probably not a good idea to go cross-country pulling a trailer behind you up and down mountains. Dr. Deb Muth 00:12:29 This is true. Bob Miller 00:12:32 So… We can get an 8-cylinder, 6-cylinder, or 4-cylinder enzyme. Now, if it’s not under a lot of stress, if that 4-cylinder car is just taking you to the bank and the grocery store. It’s just as good as an 8-cylinder car. But if you gotta pull that trailer, and there’s a lot of stress on it, being mountains, it’s gonna struggle. Now, there’s one other little caveat to this, and that is some genetic mutations are gain-of-function. They actually work faster. Now, we have enzymes that do all kinds of things. We have enzymes that make and recycle our antioxidants, but we also have enzymes that make inflammation. No, that’s a good thing, because if we get a virus or bacteria, if you didn’t make inflammation to kill it, well, we’d all die of infection. So, you know, we tend to think of free radicals as bad, antioxidants as good. They both play an important role. But interestingly, some of the major enzymes that make inflammation, they can be overactive. They can be turbocharged. And when they’re stimulated by environmental toxins, they overreact. Bob Miller 00:13:40 And therein lies the problem. When they overreact, we have a problem. Bob Miller 00:13:46 So, if we have genes that overreact when stimulated. And then the enzymes that take care of inflammation are underactive. Then you’re gonna be more inflamed. You know, the majority of people that, you know, come for functional medicine Or naturopathic help, or… Inflammation that they can’t seem to get under control. Dr. Deb Muth 00:14:06 Right. Bob Miller 00:14:07 And we will be, you know, during this hour, we’re going to look at some of the pathways that make that happen. So, what we can do then, we can’t change our genetics. When you’re conceived, that’s the hand you’re dealt. When your life would be over, if someone would take some tissue and measure, it’d be exactly the same as conception. Does it change. Bob Miller 00:14:28 The enzyme’s ability to do its job may be compromised. Because remember I said there’s a, the enzyme takes a cofactor. So an enzyme takes substance A, cofactor, make substance B. Well, if that cofactor’s not there, the enzyme’s not going to work either. So, you could have an 8-cylinder car, and if there’s no gas in it, it’s not going anywhere. So… It’s the strength of the enzyme, it’s the cofactor to do the A to B conversion. And that’s what we’re going to get into. So, many people say, well, where did these SNPs come from? Nobody knows for sure. Sometimes they’re what’s just called de novo, when the sperm and egg go together, the instructions get mixed up a little bit. We do believe a lot of it came from a long time ago, when we were almost wiped out by sexually transmitted diseases. And those STDs were altering the genes when the conception, in other words, when the sperm went into the egg, the STDs were interfering. And causing the problem, so… I often joke, if you want to blame somebody. Blame your great-great-great-great-great-great-great-grandparents for, being a bit promiscuous, so… Dr. Deb Muth 00:15:31 Yeah, for being… having a little too much fun, right? Bob Miller 00:15:35 So, we don’t know for sure, but, you know, there are some that, But most of the SNPs that we get inherit from our parents. So, if you look at a child. And you look at the SNPs. 99.9% of the time, it came from one of the parents. Dr. Deb Muth 00:15:50 In identical twins, do they have the exact same identical makeup? Bob Miller 00:15:54 Yep, Dr. Deb Muth 00:15:56 But not in fraternal twins, correct? Bob Miller 00:15:59 No, no, those could be different, Jeff. Dr. Deb Muth 00:16:00 It could be different because they have different sacs, they’re not sharing that same genetic makeup. Bob Miller 00:16:04 Yeah, so keep in mind, both your mother and your father have, you know, the two And so you get one from one parent, one from another. Dr. Deb Muth 00:16:13 So… Bob Miller 00:16:14 Interesting situation. I had, 3, 3 boys. And, we were looking at an enzyme related to breaking down oxalates. Now, the mother and father each had one SNP, and that’s called heterozygous. Three boys, and they all come together, they’re Amish boys, they’re a lot of fun. And I looked at their genomes, and the one boy didn’t have any SNPs at all. And one had won. And the other one had two. Dr. Deb Muth 00:16:41 Interesting. Bob Miller 00:16:42 So, we don’t quite know how these things get handed off, but with the parents each having one, you could have a child with none, one, or two. So, the one, his ability to break down oxalates, which is fine. The other one was slightly impaired, and the other one was dramatically impaired. So, you can have 3 children, and it all depends what the parents have. Now, if a parent has a homozygous, or 2 copies. And the other parent has nothing. Every child will have one. Okay. If both parents are homozygous, that they both have two, Every child will have two. Dr. Deb Muth 00:17:19 too. Bob Miller 00:17:20 Yes, so that’s the way it works, but, you know, but it’s somewhat rare that both parents are homozygous on an enzyme, but it can happen. Dr. Deb Muth 00:17:27 Do we think that infections today, like Lyme disease or mold exposure, things like that, if the parent, the woman, primarily, I’m thinking, is pregnant, and she actively has these infections. Can those infections affect the genetics, kind of like a past sexual transmission did where we thought back in the day? Bob Miller 00:17:47 Yeah, I… I mean, I’m not that much of a geneticist to answer that for sure, but my thought would be no, that at conception, the pattern’s made. Dr. Deb Muth 00:17:55 Okay. And then that’s… that’s the hand you’re dealt. Bob Miller 00:17:58 Yeah. So, I tell people we have good news and bad news. The good news is we can compensate for the weakness. The bad news is we can compensate for the weakness. Dr. Deb Muth 00:18:09 That is so very true. Bob Miller 00:18:11 Yeah, we can’t, because I often get asked, so we’ll do some things now, and we’ll check my genes again, and they’ll be better. It’s like, nope. Dr. Deb Muth 00:18:18 Oh, – – Bob Miller 00:18:19 You gotta play the hands you’re dealt, so… Dr. Deb Muth 00:18:21 That’s right. Bob Miller 00:18:22 You can test your genetics… if you’re looking at the same enzyme, you can test it every year. It’s not gonna change. It’s like the blueprint. Dr. Deb Muth 00:18:30 It’s good and bad, right? It’s the one test you only have to do once in your lifetime. Bob Miller 00:18:34 No, unless, you know, like, our. Dr. Deb Muth 00:18:36 All the time. Bob Miller 00:18:37 Yeah, now our test looks at, called the Functional Genomic Analysis Test of your genomic Resource. We look at 220,000 steps. Dr. Deb Muth 00:18:46 Wow, that’s a lot. Bob Miller 00:18:47 That’s not all of them. Dr. Deb Muth 00:18:49 Right. Bob Miller 00:18:50 So, maybe in the next year, we’re gonna come out with our third version of the chip. And then, if someone wants to get those new things that weren’t on it, they’d have to repeat. But whatever we measured is gonna stay the same. Dr. Deb Muth 00:19:03 That’s a lot of SNPs to look at. Bob Miller 00:19:05 Keeps us busy. Dr. Deb Muth 00:19:06 But there’s still, but there’s still SNPs that we. Bob Miller 00:19:09 That we’d like to have that we don’t have, so… Bob Miller 00:19:11 We started out with version 1 on our genetic test, then we worked with version 2, and we’re already compiling a list of what version 3 would look like. So if somebody has our version 2, And we’re saying, you know what, it’d be nice if we could see these, well, then you’d repeat, but it won’t change what you already know, so… Dr. Deb Muth 00:19:29 Got it, got it. So, when you started out, and you started looking at the research of Lyme disease and chronic infections, which detox pathways are most important for people who struggle with those conditions? Bob Miller 00:19:43 Okay. You know what might make sense as we do a screen share, and I’ll actually show you the pathway. Does that make sense? Bob Miller 00:19:48 Alright, so… let’s see if I… let me just press the share… Dr. Deb Muth 00:19:52 Yep, you should just be able to press share. Bob Miller 00:19:54 And… number 2. Okay. Are we seeing the screen there? Bob Miller 00:20:01 Okay. Dr. Deb Muth 00:20:02 So, this is a map that we made. Bob Miller 00:20:05 And by the way, this is not… All-inclusive of all the things we look at, but we believe this is a core issue. So, where we’re going to start here, there’s something called the microglia. And the microglia are glial cells. They’re in the brain and the central nervous system. And they’re very interesting little creatures, because most of the time, and this is just a drawing of what they sort of look like. Most of the time, they’re in what’s called the M2 anti-inflammatory mood. What that means, these little guys pick up dirt, debris, Recycle them. Turns on an enzyme called interleukin-10 that’s anti-inflammatory. And just kind of does general housekeeping. And just kind of does general housekeeping. However, when a trigger comes along. However, when a trigger comes along. They… it’s the same glial cell, but it moves over to a very pro-inflammatory enzyme. A pro-inflammatory glial cell. And it triggers these 3 enzymes, Actually, these four. That are pro-inflammatory. Tumor necrosis vector alpha, Interleukin-6. NF Kappa B, Inos. Now, these create inflammation. So you might think, well, why is that good? Well, if you have some foreign invader, virus, bacteria coming in, parasite. If you didn’t have these guys coming to the rescue, you would just die of infection. So, these guys are your friend unless they’re your worst enemy. Because TNFA, and we’ll show you when we actually do a demo account, TNFA can be overactive. So, in other words, it over-responds. Interleukin-6 can be overactive. And if Kappa-B can be overactive. The INOS, and I’ll explain each of these as we go through a demo, can be overactive. Now, what that means is, you’re very good at killing virus and bacteria. But this is where autoimmune disease comes in, and just inflammatory conditions. Now, this is just speculation, but we think what happened is, as you know. Thousands of years ago, we didn’t have refrigeration, we didn’t have sewer, we didn’t have pure water, and we didn’t have antibiotics. So, if you made it to 40, you were an old-timer, because everybody was dying of infection. So, what we believe happened is, by what’s called natural selection, Having these overactive. A thousand years ago was to your advantage. Dr. Deb Muth 00:22:31 Hmm. Bob Miller 00:22:32 But now… We have pure water, we have refrigeration, we have sewers, we have antibiotics. But now we have environmental factors that are stimulating them. Now it’s to our disadvantage. And we’ll talk about that a little bit as it relates to the hemochromatosis genes and maybe the G6PD. Dr. Deb Muth 00:22:48 Yep. Bob Miller 00:22:49 Now, why are we becoming so inflamed? Let’s look at the triggers. Now, one of my, favorite expressions is. I was born all the way back in 1954. Dr. Deb Muth 00:23:01 And it was a different world back then. Bob Miller 00:23:05 These are some of the triggers. And we’ll get into these, but right now, high fructose corn syrup, And the high-fat diet. High fructose corn syrup only came about in 1968. So now we’re being exposed to high fructose corn syrup. Then… we didn’t have these, these viruses like COVID. Dr. Deb Muth 00:23:26 Yeah. Bob Miller 00:23:27 Now, there’s now pretty strong evidence that COVID Was actually, you know, made as a gain of function. It’s debated, and I’m not taking an opinion on it, but there’s some people who believe Lyme disease was also a part of experimentation. Dr. Deb Muth 00:23:40 Go. Bob Miller 00:23:41 Then we have molds, and it appears as though mold is getting stronger. you know, 20 years ago, when I was seeing folks, mold wasn’t on the radar. I would say 7 out of the 10 folks we speak to today have mold problems. Yeah, 20 years ago, we talked more about mold allergy being an issue versus mold toxicity being an issue. Right. So… I know some folks are, you know, speculating what’s happening, but one of the theories out there is that EMF is strengthening mold. I don’t know if you ever heard that theory, and I don’t… Dr. Deb Muth 00:24:13 I have. Bob Miller 00:24:14 I’m not claiming it’s true, but it’s an interesting theory. Then even, you know, your black mold from water-damaged buildings. Then our air pollution is getting worse. We’re getting more toxic metals. Dr. Deb Muth 00:24:26 You know, if we have a… Bob Miller 00:24:27 You know, we’re gonna look back someday and say, what were we thinking, smearing aluminum into our armpits? The, what were we doing putting mercury in our teeth? Then, you know, glyphosate. When I was a kid, there was no glyphosate. So, all of these herbicides and pesticides. Polychlorinated biphenols, And then EMF. So, we love our cell phones, you know, and I think unless you, or in the middle of the desert, or down in a cave, you’re being exposed to EMF somewhere. So, you know, we have our cell phones with us, we have, We have Wi-Fi, the towers are everywhere. And we don’t know long-term, but we may find that this can… this creates some inflammation. And I don’t know if you get any folks, but do you have any folks that have… are they EMF sensitive? Dr. Deb Muth 00:25:16 Oh yeah, we have a whole bunch of them. Bob Miller 00:25:18 Yeah, and then if you have any TBIs, So, plenty of things here. that will stimulate into the microglia, M1. Now, you could say, well. We’re all pretty much exposed to the same thing. Why do some people get hit harder than others? So here’s where we’re gonna start. There’s an enzyme called Nrf2 and RF2. And Nrf2 is the enzyme that senses when there’s inflammation. And turns on hundreds of anti-inflammatory enzymes. We’ll show when we do the demo, you can have genetic weakness on NERF2. And NERF2 inhibits and slows down microglia M1. supports M2. Now, if it’s not complicated enough, there’s an enzyme called KEEP1. And KEEP1 inhibits NRF2. And you can actually have gain of function on keep 1, that makes Keap 1 stronger. So… A lot of the people who land on my doorstep So… A lot of the people who land on my doorstep Both parents gave a mutation on KEEP1, making it overactive. Both parents gave a mutation on KEEP1, making it overactive. Dr. Deb Muth 00:26:31 Hmm. Dr. Deb Muth 00:26:31 Hmm. Bob Miller 00:26:32 Suppressing Nrf2, nerve 2 might be weak. So, nobody’s putting the brakes on, M1. And by the same token, Nerve 2 supports M2. Then there’s a process called mTOR and autophagy. mTOR stands for mammalian tard of rapamycin, the growth of new cells. And then autophagy, taking our dead cells and recycling them. We need a balance between the two of them. If we didn’t have mTOR, the sperm and the egg would never become the baby, the baby would never become the adult, we wouldn’t make new cells. But our cells are constantly, you know, the old cells dying off. Autophagy is where we take that debris from the cell and recycle it, just like a farmer Plows the crop under at the end of the year. The dead plant then becomes the fuel for the spring, your dead cell becomes the fuel for the spring, and that’s autophagy. So we’re gonna look back someday and say, what were we thinking? We give our animals growth hormones so they get fatter faster. Oh my. So, we consume those animals, and inventory runs faster. Now, for anybody who’s, You know, maybe above 40, 45 years old. Think back when you were 12, and what did girls look like? They were primarily flat-chested little girls. Now they look like 16-year-olds. Because environmentally, we’re jacking up mTOR. So, mTOR stimulates microglia M1, suppresses microglia M2. Probably 80% of the folks we visit with. This is the part of the problem. NRF2 is weak. mTOR is strong. Environmental factors come along. And this guy gets carried away. He doesn’t do that burst and move back. Stays here. We’re calling that How environmental factors create a locked-in, pro-inflammatory. and neurotoxic phenotype. In other words, once it starts, it just keeps… Feeding upon itself. Alright, so what happens now when microglia is overactive. it triggers these 3 enzymes, TNFA, N of kappa B, And interleukin-6. Each one of these can have genetics that make them run stronger. Then it stimulates an enzyme called NLRP3, Which makes what are called inflammasomes. Now, guess what inflammasomes can be? Your best friend or your worst enemy? Because they will, if you’ve got, again, a virus or bacteria, or possibly even some bad cells in the body. They will zap them. Well, that’s good. Unless it’s overactive. Unless it’s overactive. And then what it does, through interleukin-1 beta, makes excess glutamate. And then what it does, through interleukin-1 beta, makes excess glutamate. Anxiety, gut inflammation, OCD, ADD, autism. And, you know, glutamate, we’ll talk about that a little bit, but glutamate makes you intelligent, highly motivated go-getter. but can also be excitatory. And then, look what it does. Let’s see, do I have the drawing tool here? Yes, I do. Okay. So, it comes down through here, Makes the glutamate. Comes back up through here. through the ADORA 2A enzyme, Then we’ve got a feedback loop that feeds upon itself. Then, through interleukin-18, we make histamine. and mast cells. And then through histamine receptor site number 1, we come back and spin it. And now you’ve just got this spinning feedback loop. So, the glutamate will make you anxious, the histamine will give you allergies and make you anxious. And you’re allergic to everything, and you’re feeling horrible. Now, it doesn’t end there, Dr. Dad. It then goes on to make something called gast dermins that creates pyroptosis, where it actually starts punching a hole in the cell membrane. And you’re only going to be as healthy as your cells are. Just a little background. You know, we’re made up of trillions of cells, and each one of them has what’s called a lipid bilayer, made from lipids, which comes from fats. And you’re only going to be as healthy as those membranes are. So that’s why we coined an interesting phrase. Cellular CPR. Construct the cell. Protect the cell. And restore the cell membrane. And we believe that’s going to be revolutionary in the functional medicine world. So… It’s not hard to figure out that if you start punching holes in the cell membrane, that’s not a good thing, okay? Bob Miller 00:31:22 Now… There’s an interesting molecule called NAD. Thicotide adenoside dinucleotide. And anybody who’s in the, you know, listening to the health podcasts and things, they’re… They’re, they’re learning about NAD. And I’m going to show you a chart later, all the good things that NAD does, but For the most part, it helps what’s called sirtuins. And sirtuins are quite interesting. If anybody’s looking at longevity. The sirtuins is where they’re looking at.Because sirtuins turn on good things. Turn off bad things. And I’ll show some charts on that later. So for right here, this sirtuin uses NAD, to slow down NF-kappa-B. CERT 2 uses NAD to slow down an ORP3. So, if we’ve got genetic weakness on these, or we don’t have enough NAD, We don’t hold this pathway back. Make sense? Dr. Deb Muth 00:32:24 Yeah, makes perfect sense. Bob Miller 00:32:25 Now, I’ll show this a little bit later. So, people are like, oh, well, I’m gonna start taking some NAD. Dr. Deb Muth 00:32:31 Right. Bob Miller 00:32:32 And there’s functional doctors who give NAD intravenous. It was just this morning, I was talking to a woman who said, Oh my gosh. I went and got intravenous NAD, and it took me a month to recover from that. Dr. Deb Muth 00:32:45 Hmm. Bob Miller 00:32:46 what happens is, and I’ll show this in a little more detail, there’s an enzyme called CD38, that’s stimulated by NF-kappa-B. And it takes NAD, To make intracellular calcium. that stimulates NLRP3 and actually makes things worse. So, if we have this guy upregulated, and I’ll show a chart what does that. taking NAD will make you worse. Again, when I go into the software, I’ll show you that whole pathway, so… I would encourage people, you know, just don’t go out and start taking massive amounts of NAD, you know, stick your toe in the water, see how you do. Because everything you’ve heard about, how good it is, is true, unless this guy says, oh, thank you very much, let me make more inflammation. Now, this might be part of our innate immune system, that if we have some pathogen that’s gonna kill us. By golly, we want that to happen. But if this is happening by environmental factors, Then it’s detrimental. So the immune system that protected us a thousand years ago now might be turning on us because of the environmental factors that we showed earlier. All right. Then there’s an enzyme called PARP that’s NAD-dependent, and that actually repairs strain breaks in your DNA. Now, the next thing that happens… is there’s an enzyme called NADPH oxidase that gets stimulated. and something called INOS. Now, I’m sure most people know about nitric oxide. It’s a gas that dilates your blood vessels. That’s why sometimes they’ll even give people drugs, nitroglycerin, to boost their nitric oxide. That’s why people are doing beetroots and other things to boost their nitric oxide. But there’s an OS3 enzyme that makes the nitric oxide that’s good for blood flow. But there’s an INOS That makes nitric oxide to kill pathogens. probably might be the third or fourth time I’ve said this. That’s a good thing, unless it isn’t. So, if it’s killing some pathogen, great. It was just misfiring. it combines… With superoxide that’s made by this enzyme, and makes something called peroxynitrite, which is one nasty free radical that chews you up and spits you out. So, the NOx enzyme, NADPH oxidase, uses NADPH, To make this free radical called superoxide. If we have time, we’ll get into it. NADPH is what your body needs to recycle your antioxidants.So, I coined the phrase, the NADPH steel. Where the NOX enzyme takes this very important NADPH, And rather than being useful, makes superoxide. Now, again, is that fine if you’ve got some bacteria to kill? Of course. But if it’s just chronically running, it’s just making all this chronic inflammation. Then it makes something called hydrogen peroxide. And we need to clear hydrogen peroxide by 3 enzymes, catalase, thyroid reduction. And glutathione peroxidase. If we have genetic issues on here, or we don’t have the cofactors. There’s something called the Fenton reaction, discovered in 1895 by Dr. Fenton. Where hydrogen peroxide combines with iron to make what are called hydroxyl radicals. And guess what they do? They create lipid peroxides, That damages your cell membranes. Now, again, the body’s pretty darn amazing. We have glutathione, And here’s where your body’s taking glutathione and recycling it. But look who’s needed to recycle it. NADPH. So, if this guy up here is chewing it up, We don’t recycle our glutathione. And then an enzyme called glufon peroxidase 4, Takes this damaged lipid and repairs it. So, here we’ve got this protecting, we want to protect it by not having this happen. But then we also need this guy to do the restoration. So, there’s a lot that can go wrong in here, Dr. Deb. Dr. Deb Muth 00:37:07 There’s a lot that could go wrong. And I can imagine some of my listeners are thinking that lipid peroxidase, is that the same thing as what they’re thinking of when we talk about lipids and cholesterol? Is that the same process that’s happening there? Bob Miller 00:37:22 Well, no, no, the lipids can be used to make cholesterol, but here we’re talking about where they’re going to build the cell membrane. And they’re being… and they’re being, destroyed. If anybody would like to see a visual representation of this, just go on YouTube. And type in, ferrooptosis Animation. cool little video, it’s about 3 minutes long, and it shows the lipids coming over, being oxidized, and now GPX4 fixes them, so… YouTube, Pharaoptosis Animation, cute little video. It’s just that really… Shows vividly what we’re… what we’re talking about here. Now, this is… Dr. Deb Muth 00:37:59 And so this is very common, too. Like, a lot of people do hydrogen peroxide IVs. Dr. Deb Muth 00:38:04 And so, if somebody doesn’t know their genetics, they could have a problem with doing those, just like they could doing the NADHIVs, correct? Bob Miller 00:38:13 Sure, yeah, yeah, yeah. So, I’ve talked to so many, you know, of course, the hydrogen peroxide kills pathogens. I mean, that’s what it does. So… but I’ve spoken to so many people that said. I had one client that said they’ve never been the same after having one hydrogen peroxide infusion. Dr. Deb Muth 00:38:30 Interesting. Bob Miller 00:38:31 Yeah. So… it can be… I see why people use it, because it. Bob Miller 00:38:36 pathogens, But on the other hand. And now’s a good time to speak about… I don’t have it on here, but there’s a, there’s an enzyme called the HFE gene. And that is what causes you to absorb iron. And there’s mutations in it that cause something called hemochromatosis. Were you overabsorb iron? Now, true hemochromatosis is when both parents give you a mutation. But there’s now growing evidence even a heterozygous can cause a little bit more iron absorption, not to the human chromatosis point, but overabsorption. So, if you overabsorb iron, And you have too much hydrogen peroxide that’s not cleared, All kinds of inflammation. Now, what’s happened is sometimes this inflammation Will damage the red blood cells. And some well-meaning doctor says, oh, you need some iron. And they take iron and it makes it worse. So, can’t tell you how many people I’ve said, you’ve got the overabsorption of iron, and they say, well, that can’t be right, because I’m low in iron. Well, that could be because it’s being chewed up here. Dr. Deb Muth 00:39:40 Sure. GPX1 and TXN turn it into, to water. The, catalase turns it into water and oxygen. Dr. Deb Muth 00:39:58 Now, I see a lot of my clients who have mutations or SNPs on that GPX gene, on that glutathione gene. And they really struggle to clear a lot of their toxins. Bob Miller 00:40:12 Sure. Dr. Deb Muth 00:40:14 Yeah, absolutely. Well, GPX4. Bob Miller 00:40:18 is what, repairs, but you can see GPX1 Is what uses glutathione. To turn hydrogen peroxide. So, but it all depends upon having enough glutathione. Dr. Deb Muth 00:40:30 Yeah. Bob Miller 00:40:31 Well, guess who controls making a glutathione? Dr. Deb Muth 00:40:34 Nerf 2. Bob Miller 00:40:37 So, if you have a keep one weakness, or strength to two… I’m sorry, keep one is too strong. Nrf2 is too weak. You don’t make glutathione. So, when a lot of people do that, it’s like, well, I’m gonna take glutathione. Dr. Deb Muth 00:40:51 Right. Bob Miller 00:40:52 And some do great, and some do poorly. You know, because… and I’ll show this on one of the other charts. You can see here that the, The glutathione has to be recycled. And if we don’t recycle it, it actually turns into superoxide free radical. So… NADPH are the cofactors, For taking the oxidi… here’s oxidized glutathione, here’s reduced. So, this is a good glutathione. After it does its job, you can see it becomes oxidized.We need to recycle it. Well, if we have weakness on the enzyme that does that, or a weakness in Nrf2, or not enough NADPH. The oxidized glutathione never gets recycled. So, I’ve talked to a lot of people who said, oh, glutathione made me so sick, and say, well. Dr. Deb Muth 00:41:43 Yeah. Bob Miller 00:41:44 You need it, but you need to recycle it. Dr. Deb Muth 00:41:46 Can you speak for just a brief moment, too, about MTHFR? That is a very popular gene, it’s all over social media as the major gene, but can you speak to a little bit about that, and how that fits into this whole process of things? Because it is just such a small piece. Dr. Deb Muth 00:42:04 understanding genetics. Bob Miller 00:42:06 Yeah, to be honest, it drives me nuts. Dr. Deb Muth 00:42:08 Me too. Bob Miller 00:42:11 Alright, so… You know, there are people on social media I won’t say what I think, I’ll be kind. But… But the, And, you know, they might mean well. But they talk about, if you have MTHFR and COMT and PEMT, that’s… oh my goodness, that’s horrible, and we’ll fix that for you, and you’ll be fine. Bob Miller 00:42:36 it just irritates me to no end. And it really could get anybody who’s doing this legitimately in trouble. I mean, I’m afraid someday, you know, there might be some cracking down on this kind of nonsense. Now, to answer your question about MTHFR. Dr. Deb Muth 00:42:51 I mean, it really is, but I’ll tell you what, why don’t we hold that thought until I go to another map and I can actually… Okay. Bob Miller 00:42:56 But the real… the cliff notes is the MTHFR puts a methyl group on your folate, which is needed, but it has gotten way, way, way too much attention. And people learn they have MTHFR, and they start taking a multivitamin with methylfolate, then they take a B vitamin with methylfolate. Dr. Deb Muth 00:43:13 And they’re pushing it too hard. Bob Miller 00:43:15 Yeah. So I can’t tell you how many people I’ve helped by saying, stop it. Dr. Deb Muth 00:43:20 Yeah, take less of it. Bob Miller 00:43:21 Take less of it, yeah. So, yeah. Yeah, there’s a… If somebody, say, ranked the enzymes at their level of importance, MTHFR might be 40 or 50 on a scale of 100, you know. Keep one Nerf two. big deals. Dr. Deb Muth 00:43:40 deals. Bob Miller 00:43:41 NQO1 that I didn’t even talk about yet, NQO1, takes your, NA… your NAD goes into NADH, To make electrons for the electron transport chain. you need NQ01 to bring that back. If that’s not working, and I’ll show you on the NAD map how disastrous that can be. Now, the next piece is here, and I think You know, if you talk to any school teachers and say, if you’ve taught for more than 10 years, how are the kids today? Every one of them says, more ADD, ADHD, more autism. Just look at human beings, we’ve never been so agitated. You know, everybody, and it might be a social media thing, but people take a position on something, and if anybody doesn’t share that position, they view them as the enemy. Dr. Deb Muth 00:44:29 And it’s kind of scary what’s happening to us. Bob Miller 00:44:33 So, we can’t agree to disagree anymore. We see anybody who has a differing opinion as the enemy. And, you know, there was… there’s people that didn’t have Christmas dinners together, because they had political differences, like… Dr. Deb Muth 00:44:44 Excuse me. Bob Miller 00:44:45 can’t you put your political differences aside to have Christmas together, you know? Dr. Deb Muth 00:44:49 Right? Bob Miller 00:44:50 become that, you know, no matter what your position is, and I’m not saying anyone’s right or wrong, I’m just saying. You know, in the old days, they used to say that the Republicans and Democrats in Congress would argue policy and then go have dinner together. And now everybody’s all up in arms, angry. Dr. Deb Muth 00:45:05 Yeah. Bob Miller 00:45:06 So… There’s likely multiple reasons for that. But let me show you one of them. That, you know, to what degree this is… very important, we don’t know, but I think We’re beginning to believe this is very important. So, there’s something… there’s a neurotransmitter called GABA. And God buys the don’t worry, relax, be happy. Chill. Okay. Dr. Deb Muth 00:45:31 Nobody has enough of that anymore. Bob Miller 00:45:33 Well, yeah, you’ll be surprised what I’m gonna show you. So, let me see if I can find a, Let me see if I can find the right slide here. Let me look for it here. So, there’s something called a GABA receptor site. And here you can see… This is a neuron, and this is where you, The neuron normally is excitatory. However, there’s normally low chloride in the neuron. Dr. Deb Muth 00:46:09 Hmm. Bob Miller 00:46:10 So, GABA itself is neither relaxing. For excitatory, all GABA does, it opens up what’s called a chloride channel. And then chloride, which has a negative charge, will flow into the neuron. Follow me there? Dr. Deb Muth 00:46:26 Yep. Bob Miller 00:46:27 And as it does, it changes this from a positive charge to a negative charge, And it’s relaxing. and inhibitory. Dr. Deb Muth 00:46:34 Hmm. Bob Miller 00:46:36 Now, on the other hand, there’s enzymes called NKCC1, That will push chloride in. and KCC2 that will bring chlor… oops and bring chloride out. And then there’s a sodium channel. And, sodium has a positive charge. And glutamate will push that in. So, as long as this is happening. And GABA says, receptor sites, open, chloride goes in, Chill. However, If NKCC1 Pushes extra chloride in. KCC2 doesn’t pull it out. and GABA hits the receptor site, the GABA comes flowing out, Sodium comes in, And now it’s excitatory. So Gabba didn’t change. GABA just opened the receptor site, that’s all it does. Dr. Deb Muth 00:47:33 Yeah. Bob Miller 00:47:34 But it’s the chloride balance that’s going to determine whether this is relaxing or not. Now, these are the things that go along with when they lose that KCC2 or gain NKCC1. Pain and sensitivity, burning electrical, neuropathic pain. Normal touch hurts. Sound and light sensitivity. Tinnitus can flare. Headaches and migraines. Seizure tendency. Body jolts. Spasticity, cramps, stiffness, startle reflex. Trouble falling asleep, non-restorative sleep. Anxiety, stress, reactivity, that’s what we have now. Hyperarousal, panic-like surges, irritability, racing thoughts. Brain fog, slowed processing, working memory slip-ups. Mental fatigue. Episodes of racing hearts, sweaty palms, guts on edge. Those are all the things that happen when this GABA switch occurs. Now, here’s what happens, and this is what I’m going to be presenting at an autism conference. When you have a newborn, they need that NKCC dominant to develop. By early childhood, it should… or, sorry, early adulthood. we should move over to the KCC dominant, that’s the taking the chloride out. Nice-looking 25-year-old boys, functioning very well. However, when we get microglia M1 upregulated. Because of environmental toxins, processed foods, Tylenol, aluminum. they stay in NKCC1 dominant, and there’s ADD, ADHD, Autism, the whole spectrum. because… They’ve not moved over to the… They’ve not moved over to the KCC2. And again, this is caused by… Environmental factors. Stimulating the microglia. And then, interleukin-1, interleukin-18 weakens KCC2, interleukin-1 beta, Strengthens NKCC1. high chloride. We open up the chloride channel, In Rebell Excitatory. So, I think when, When the pediatricians get ahold of this, they’re going to be very excited to know that This could be why we’re seeing such a rise, and not just autism, but ADD, ADHD, anxiety, the whole shit mess. Dr. Deb Muth 00:49:58 thing. Bob Miller 00:49:59 Yeah, so… and you can see NF-kappa-B stimulates that. These stimulate it, and I think that’s why everyone’s getting so anxious. Now, there’s a little bit more to it, and we’ll get into this when we look at some of the maps, but… The, the glutamate, Which is excitatory. will stimulate the NMDA receptor, make more glutamate, And glutamate will inhibit KCC2. And then we also need an astrocyte To, take both ammonia And glutamate, and… Turn them back into glutamine. And I’m going to talk to you a little bit about arachidenic acid, and if we have too much arachidenic acid. or TNFA is upregulated, that doesn’t happen. Ammonia goes up, and there may be multiple reasons for this, but this is a reason why some of the autistic kids do flapping. Dr. Deb Muth 00:50:49 Hmm. Bob Miller 00:50:50 Because they’re not clearing their ammonia. And you can tell if somebody has high ammonia by… they get that old person smell, you know. Dr. Deb Muth 00:51:00 Yup. Bob Miller 00:51:01 your vehicle cycle’s not taking out the, the ammonia. Now, last pathway here. There’s growing interest in mast cell activation. So, back here, we talked about peroxynitride. And that will stimulate mast cells, and those are white blood cells that are your best friend, unless they’re your worst enemy. Then it’ll make histamine. And there’s enzymes called histidine decarboxylase that’ll make more. Dr. Deb Muth 00:51:28 I’m sure everybody’s heard of DAO, the enzyme that degrades histamine. Yep. Bob Miller 00:51:31 We can have genetic weakness, we don’t make that. There’s an enzyme called histamine and methyltransferase, That, That breaks down the histamine. Then if we don’t do that, it’ll get stuck in the histamine receptor site. And then it’ll make something called, renin. Which will cause angiotensinogen to turn into angiotensin. One, that turns into angiotensin II,And that’s where people make aldosterone, where they’ll get the, The swollen ankles and high blood pressure. But interestingly, there’s an enzyme called ACE2, that takes this guy and turns it into angiotensin 1-7, Which is anti-inflammatory and also inhibits… TNFA. Now, you can have weakness on ACE2, But… and anybody’s saying, that sounds familiar? Dr. Deb Muth 00:52:25 That’s where COVID comes in, using ACE2. Bob Miller 00:52:28 And now we just found there’s literature that if you get COVID long enough, it can actually make ACE2 not be able to work as well. So look what it does. It comes down here, stimulates the NADPH oxidase, More superoxide. More peroxynitrite. And we’re on a cycle here. We’ve actually named this the Home Cycle Hypothesis, the proposed feed-forward loop. That just keeps feeding on itself. All being caused by… Primarily, The environmental factors. But hitting those who have genetic weakness the hardest. That’s why. Dr. Deb Muth 00:53:08 To the people. Bob Miller 00:53:09 Don’t live in a moldy house. One person is sick as can be, and the other person says, well, you must be imagining things, because I don’t feel anything. Dr. Deb Muth Yeah. Same thing with long haul, right? Two people can both get sick, one gets sick and never seems to recover, and somebody else gets sick, and they have absolutely no problems with it at all. Bob Miller 00:53:30 Sure. Well, think about it, if you get COVID, and ACE2 is weak, and some of this other stuff is going on. This thing just starts feeding upon itself. Dr. Deb Muth 00:53:38 Keep creating more inflammation, more complications, nothing’s calming down. Bob Miller 00:53:43 Yeah. Now, you, you ask about, MTHFR. So, this is the, this is the, the software called Functional Genomic Analysis. There’s a demo report we have. So, let’s talk a little bit about, MTHFR. So, we actually have a map called a methylation map. Now, what happens is, when you do your saliva test, you, you know, you spit, you put some saliva. in a collection kit, goes to a lab, takes out the DNA data, sends it to the computer, and now you can actually see it visually. Okay. So, it’s gonna take a second for this, data to load up, it’s, and each of these Circles, each of these ovals, is an enzyme. And the data gets loaded up to see where it is. So, until it gets loaded up here, I didn’t preload this. There it goes. So… The primary thing about methylation is There’s a nasty substance called homocysteine that, if it’s too high, can really be detrimental. The body takes methylfolate, and combines with methyl B12, To bring this back up to methionine. And then through the MAT genes, we make SAMI, S-adml methionine. Which is involved in so many processes. Then after it does its thing, it turns back into homocysteine. And this thing needs to keep spinning around. That’s why, you know, it’s a good idea to keep homocysteine at, do you have a number that you’d like? 7, 8? What do you like for a number? Dr. Deb Muth 00:55:24 Yeah, I like mine below 7. Bob Miller 00:55:26 Yeah. So if the homocysteine goes too high. It, caused all kinds of problems. So, here’s where you ask about the MTHFR. So, here you can see on this individual. I click on MTHFR, and you can see it comes up here, here’s the C677. And you can see here where it says, variants. I’ll… I’ll draw in case somebody’s having a hard time seeing that. So, you can see there’s nothing in there. That means there’s no genetic mutations. If one parent would have given a mutation, there’d be a 1. If both parents did, there’d be a 2. Now, here’s why Yes, methylation is important, I’m not saying it isn’t important, but look at this MTHFRC677. In my software. Only 42.5% of the population does not have a mutation. 44.7% have won. 12.9 have 2. So, this isn’t some rare, oh my god, I’m gonna die… Kind of thing, yeah. Dr. Deb Muth 00:56:27 Right. Bob Miller 00:56:28 So, And then what happens is that, and again, I’m not dismissing methylation, I… we could do a whole show on methylation. Bob Miller 00:56:36 get it. But I think that what people are doing is they’re, they’re learning about MTHFR, they get it measured, they panic. They start taking massive amounts of methylfolate, which many times is to their detriment. Dr. Deb Muth 00:56:50 Well, it’s… and isn’t it true, too, with MTHFR, like, you have to also look at MTR, MTRR, and the more we stack up of those, the more complicated than MTHFR can be. It’s not… it’s not as simple as just saying MTHFR 677 versus 1298. It’s more complex than that, kind of like what you’ve already shown with some of the other things. There’s more to it than just that one little sliver. Bob Miller 00:57:17 Oh, sure, well, let’s take a look. So, remember I said there’s a cofactor? One of the cofactors is called FAD. Just a Bob Miller observation, that’s all. But when people have trouble with their riboflavin and they don’t have enough FAD, They’re doing much worse than people who have just a C677. So, right here, you could have perfect C677th. And if you don’t have the cofactor, it’s not gonna work, okay? Dr. Deb Muth 00:57:48 And as you said, there’s an MTR enzyme. Bob Miller 00:57:51 that takes methylfolate and methyl B12, to spin it around. So, here on this individual. here’s your… here’s your B vitamins, or I’m sorry, your B12s. There’s an enzyme called TCN1 that takes it from the stomach into the blood. Then there’s other enzymes that take it from the blood into the tissue. And if you’re having trouble here. Well, then you’re not going to have this working, so… Even if you don’t have MTHFR, And you have MTR, like this, no, I’m sorry, this person doesn’t. But they have the MTRR, and then they don’t have enough B12, this isn’t gonna work, aside from that. And then there’s a middle pathway. And then there’s enzymes called the MAT1. they take the methionine to the salmon. If that’s not working, we stick… we get stuck in methionine. So, it’s, it’s not just an MTHFR. And then, one of the things that people forget about. is through these CBS enzymes and CTH, We make cysteine, which is needed to make glutathione. The master antioxidant. So, it really is that… I call it the, The 3D chess game played underwater. Dr. Deb Muth 00:59:07 It really is. I mean, I see people who have CVS, COMT, glutathione, MGHFR genes. And some of them function just fine. Like, they have Like, I look at this person and I’m like, oh my gosh, I don’t know how they’re functioning because they’re double mutated on so many pathways, but yet they don’t have a lot of symptoms, they don’t have a lot of complications. Somehow their body has figured out a way to adapt to what it has so it can stay alive and it can function at a high functioning level. Bob Miller 00:59:36 Yeah, and they may be, you know, eating right? Yeah. Staying out of a moldy house. reducing stress. So, it’s diet, it’s stress, it’s genetics, environmental factors. So, yeah, we can’t just say somebody’s gonna be good or somebody’s gonna be bad. You know, some people get scared, oh, I got all these, it’s like, well… Bob Miller 00:59:56 Are you living in a moldy house? You know, and if you live in a moldy house and your glucuronidation pathway doesn’t do well, or if you’re, you know, a smoker, or you’re constantly eating junk food, I mean, all. Bob Miller 01:00:07 things come together. Although, you know, when we focus on genetics, we’re well aware that this is just a piece of it. You know, you could have identical twins, Genetically, and if one… Is exposed to mold and smokes and drinks and stressed out. They’re gonna be a whole lot sicker than their sibling. Bob Miller 01:00:28 Yep. Dr. Deb Muth 01:00:29 Yeah, it’s that concept of taking twins, and one gets raced with one family, and one gets raced with another family, and they don’t have the same… problems that… that each other have, you know? It’s a very unique situation, we don’t think about that enough. Bob Miller 01:00:44 Alright, so again, genetics loads the gun, environment pulls the trigger. So, if you’ve got a loaded gun, but you don’t have the triggers, you’re okay. Dr. Deb Muth 01:00:53 Yeah. Bob Miller 01:00:54 Yeah. So, remember I said I was going to talk about NAD? So, here’s NAD, and what it does, it turns into NADH. And what NADH does, it, Comes down this pathway, what’s called the electron transport chain. And that makes your ATP, that’s your energy. So, if this wasn’t working, we wouldn’t be alive, because we wouldn’t have energy. So it donates an electron, that’s why it’s called electron transport chain. So, we need NAD, To make this, to make the energy. But remember I said that NQ01, this would probably be, like, on my top 10 list of… Bob Miller 01:01:36 Much more important than MTHFR. This one takes NADH back to NAD. If we’re stuck over here, We’re low in this NAD+, But what happens is, NQO1 also provides CoQ10. And CoQ10 Is what’s needed for the electron transport chain to flow. So if we get too many electrons up here. And they don’t turn them into energy. They make a nasty free radical called superoxide. Okay. Now, NAD plus also makes NADPH, And that is needed. Remember I said we need to recycle our antioxidants. So, if we have a problem with FAD from riboflavin. Yeah, we don’t have enough NADPH, Glutathione’s not getting recycled, and you’re gonna be inflamed. And you take glutathione, you’ll feel worse. There’s another enzyme called thimoredoxin. Same thing, needs NADPH and FAD. And same way with your nitric oxide, there’s an enzyme called NOS3, That makes the nitric oxide that dilates your blood vessels. And if we don’t have enough NADPH or fat, You’re gonna make superoxide. Rather than nitric oxide. Now, remember

Great science doesn't always translate into a scalable product, and that gap can stall even the most promising innovations. In this Mol Bio Minutes episode, Steve Lewis explores a common challenge in biotech: moving from a validated assay or prototype to a commercially viable product. While scientific teams often achieve strong early results, scaling requires coordination across design, engineering, materials, and manufacturing, which typically involves multiple vendors. This fragmented process introduces delays, misalignment, and risk. The episode highlights how physical product design, especially for consumables like microfluidic cartridges or custom plastics, can ultimately determine whether a solution reaches the market. By integrating design, prototyping, and manufacturing under one roof, Thermo Fisher Scientific's Plastics Prototyping Services aim to streamline this transition. Early consideration of materials, manufacturability, and reagent compatibility enables faster iteration and more efficient scale-up, particularly for startups navigating growth stages. Ultimately, the message is clear: if your biology works but your product doesn't scale, the problem is solvable. With the right integrated approach, innovation doesn't have to stall, it can move efficiently from idea to impact. Helpful resources and links: Learn more about Thermo Fisher Plastics Prototyping Services Access information about reagents and raw materials for use in your product(s) Subscribe to get future episodes as they drop and if you like what you're hearing we hope you'll share a review or recommend the series to a colleague.  Visit the Invitrogen School of Molecular Biology to access helpful molecular biology resources and educational content, and please share this resource with anyone you know working in molecular biology. For Research Use Only. Not for use in diagnostic procedures.

Are the Fab 5 wafer fab equipment companies — ASML, Applied Materials, Lam Research, Tokyo Electron, and KLA Corp — still worth buying at today's valuations? CSI breaks down 20 years of revenue data across the five companies that control roughly 70% of annual global fab equipment spending, and explain why 2026 and 2027 are shaping up to be record revenue years — with a potential speed bump in 2028 worth watching.The conversation also covers the wave of creative M&A reshaping the equipment landscape: the Axcelis and Veeco merger nearing final approval, Onto Innovation's strategic equity stake in X-ray imaging firm Rigaku, and Applied Materials' targeted acquisition of an advanced packaging segment from ASMPT.But the most overlooked part of this episode is the introduction of the Lab 7 — a group of life science and laboratory capital equipment companies, including Thermo Fisher, Agilent, Bruker, and Revvity, that share surprising structural overlap with semiconductor supply chain investing. CSI explains why these companies could serve as a diversification play for semiconductor-heavy portfolios, and why the two industries may begin to converge.If you're wondering how to stay invested in the semiconductor supply chain without overconcentrating in a handful of names, this episode gives you a research-backed framework for thinking about it.Topics covered:- Fab 5 revenue breakdown and 20-year performance- Is wafer fab equipment overpriced in 2026?- Axcelis + Veeco merger update- Onto Innovation & Rigaku X-ray partnership- Applied Materials acquires ASMPT packaging segment- Introducing the Lab 7: life science meets semiconductor- Portfolio diversification beyond the semiconductor supply chain- Semiconductor market cycle outlook through 2028 and beyondFor in-depth stock research and the Semiconductor Insider membership, visit chipstockinvestor.com. Use fiscal.ai/csi for 15% off any paid plan.

-- On the Show: -- Don Lemon, journalist and host of The Don Lemon Show, joins us to discuss Trump's political prosecution against him following his coverage of an anti-ICE protest at a Minnesota church -- Modern politicians increasingly prioritize viral clips, livestream culture, and audience loyalty over policy expertise and effective governance -- Donald Trump posts a statement claiming Middle Eastern leaders begged him to delay an Iran attack, while Fox News reframes his retreat -- YouTube impressions for left-leaning media collapse by roughly 30 percent while subscribers report videos disappearing from their feeds -- Donald Trump delivers rambling healthcare remarks, praises a taxpayer-funded settlement benefiting allies, and attacks voting by mail -- Candace Owens, Alex Jones, Anthony Scaramucci, and other figures openly discuss Donald Trump's instability and possible removal -- Donald Trump reportedly bought Thermo Fisher, Micron, and Dell stock shortly before praising the companies in speeches and TV appearances -- JD Vance, Pete Hegseth, and other MAGA figures imitate Trump's speaking style but fail to replicate his chaotic charisma -- On the Bonus Show: Elon Musk loses OpenAI lawsuit, Kamala Harris calls for court-packing and adding states, Trump's corrupt stock trades exposed, and much more... ✉️ StartMail: Get 50% OFF for a year subscription at https://startmail.com/pakman

Drug development is a high-risk endeavor, typically requiring 12 years and $2 billion to bring a single product to market, with a 90% failure rate. In this episode, Saurabh Mukherjea and Kumar Mayank discuss how Artificial Intelligence is being used to navigate these challenges by solving long-standing biological puzzles and streamlining the preclinical research phase.The Challenge of Protein FoldingFor decades, scientists faced Levinthal's Paradox, which suggests that a protein chain can take more shapes than there are atoms in the universe. Understanding these 3D structures is essential for developing drugs to treat malfunctions yet identifying them via traditional methods is a costly and laborious process.The AlphaFold BreakthroughWe explore the impact of AlphaFold2, the AI predictive model from Google DeepMind that won its creators the 2024 Nobel Prize for Chemistry.→ Speed: AI can predict protein structures in minutes rather than years.→ Accuracy: The model was trained on ~140,000 structures to achieve high predictive accuracy.→ Efficiency: Experts believe AI could shorten the preclinical research phase by approximately two years.The Global AI Value ChainWe examine the commercial infrastructure that powers this revolution.To sustain these advancements, a complex supply chain is required:→ Companies like Thermo Fisher and Idexx are integrating AI into R&D and diagnostics to increase efficiency.→ Firms like ASML and TSMC build the essential chips.→ Hyperscalers such as Microsoft, Amazon, and Alphabet provide the necessary capacity for complex simulations."While researchers are using AI to decode the body's source code, the commercial side is using it to fix a broken, expensive system."

In this Mol Bio Minutes mini-episode of Speaking of Mol Bio, Dr. Andrea Hunger walks listeners through the practical differences between three core PCR approaches: endpoint PCR, quantitative PCR (qPCR), and digital PCR. Drawing on her experience in both academic research and industry, she explains how each technique provides different types of information and why choosing the right one depends on the biological question being asked.  Endpoint PCR is the simplest method and is ideal for basic presence-or-absence questions such as confirming cloning success or genotyping samples. While fast and accessible, it does not provide quantitative information. For experiments requiring measurement of gene expression levels or comparisons between samples, qPCR offers a powerful solution by monitoring amplification in real time and using Ct values and standard curves to estimate starting concentrations. Hunger then discusses digital PCR, a newer technology that partitions samples into many micro-reactions to enable highly precise, absolute quantification of nucleic acids. Because it counts positive and negative partitions directly, digital PCR is especially valuable for detecting rare mutations, low-abundance targets, and applications like liquid biopsy analysis. Ultimately, she emphasizes that these PCR approaches are complementary tools, and the best experimental strategy is to choose the method that provides the level of information required for the next step in a research workflow. Helpful resource links mentioned in this episode:  Access educational eBook covering all three types of PCR and their use in gene expression analysis.  Watch a video on when to choose digital vs. real-time PCR.  Use the PCR primer design tool from Thermo Fisher.  Access Harvard's PrimerBank, a public resource of PCR primers. Subscribe to get future episodes as they drop and if you like what you're hearing we hope you'll share a review or recommend the series to a colleague.  Visit the Invitrogen School of Molecular Biology to access helpful molecular biology resources and educational content, and please share this resource with anyone you know working in molecular biology. For Research Use Only. Not for use in diagnostic procedures.

In this episode of From Lab to Launch, we're joined by Noreen Hong, VP and General Manager of Thermo Fisher Scientific's Growth Protection and Separation business. Noreen shares insights from her extensive career, including what has kept her at Thermo Fisher for so many years and how a strong mission-driven culture and commitment to people development can shape lasting leadership. She discusses the importance of creating more inclusive hiring practices in STEM, encouraging women and underrepresented groups to pursue opportunities even when they don't meet every requirement. Noreen also reflects on the value of trusting your instincts and taking smart risks to accelerate career growth. The conversation explores how labs can operate more sustainably through equipment upgrades and better data traceability, and looks ahead to the impact of AI and connected technologies in transforming modern laboratories. Qualio website:https://www.qualio.com/Previous episodes:https://www.qualio.com/from-lab-to-launch-podcastApply to be on the show:https://forms.gle/uUH2YtCFxJHrVGeL8Music by keldez

Podcast family, we have to be careful what we ask for…Because we might just get it! We have been asking for new ways to predict preeclampsia for close to two decades. Well now we have new biomarker serum tests that are even offered direct- to-consumer. The problem is, what do we dowith a positive test?! In a past episode we covered an FDA cleared serum test by Thermo Fisher for use in patients already diagnosed with preeclampsia. Now there is a new blood test which uses cell free RNA, drawn between 18 and 22 weeks of gestation, which can also predict preterm preeclampsia. Does this work? And what do we do when the result shows “high risk” It's a complicated issue. Wehave to be careful what we ask for. Listen in for details!1.     https://publications.smfm.org/publications/554-acog-clinical-practice-update-biomarker-prediction-of-preeclampsia/2.     ACOG Clinical Practice Update: BiomarkerPrediction of Preeclampsia With Severe Features June 20243.    https://www.healthywomen.org/tech-talk-hp/tools-to-predict-preeclampsia4.     Elovitz, M.A., Gee, E.P.S., Delaney-Busch, N. etal. Molecular subtyping of hypertensive disorders of pregnancy. Nat Commun 16,2948 (2025). https://doi.org/10.1038/s41467-025-58157-y5.     https://www.businesswire.com/news/home/20250717476669/en/New-Study-in-JAMA-Network-Open-Shows-Current-Approaches-to-Assessing-Preeclampsia-Risk-Are-Failing-the-Majority-of-Pregnant-Moms

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Alessandro Maselli, President and Chief Executive Officer at Catalent and Franco Negron is the Chief Executive Officer at Simtra BioPharma Solutions.   Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology ecosystem with his esteemed guests during a live fireside chat at the DCAT Morgan Stanley CDMO CEO Dinner.   Alessandro Maselli is the President and Chief Executive Officer of Catalent, having assumed the CEO role in July 2022 after serving as the company's President and Chief Operating Officer since February 2019.  He has been with Catalent since 2010 and has played a central role in shaping the company into one of the world's leading contract development and manufacturing organizations serving pharmaceutical, biotechnology, and consumer health customers globally.   Alessandro joined Catalent as Director of Operations at the company's pharmaceutical, nutrition, and cosmetics facility in Italy. Over the course of more than a decade, he progressed through a series of increasingly senior leadership roles, including General Manager of the Zydis® operations in Swindon, U.K., Vice President of Operations for Europe within the Drug Delivery Solutions business, and Senior Vice President of Global Operations. In these roles, he oversaw multi-site global manufacturing networks, large-scale capacity expansions, and complex technology platforms across oral solid dose, biologics, and advanced delivery modalities.   As Chief Executive Officer, Alessandro led Catalent through the COVID-19 pandemic, during which the company played a critical role in the global response by supporting vaccine and therapeutic manufacturing at unprecedented scale. More recently, he has overseen Catalent's transition to private ownership following its $16.5 billion acquisition by Novo Holdings, positioning the company for long-term investment and growth as a privately held global CDMO.   Prior to joining Catalent, Mr. Maselli held a range of operational and business leadership roles at ABB Group, Alstom, and SGS, gaining extensive experience in industrial automation, engineering, and large-scale manufacturing operations. He began his career as an automation systems engineer in the food industry. In addition to his executive role, Alessandro serves on the Board of Directors of Graphic Packaging Holding Company, to which he was appointed in May 2025. He holds bachelor's and master's degrees in electronic engineering from the University of Rome and is a native of Italy.   Franco Negron is the Chief Executive Officer of Simtra BioPharma Solutions, a leading sterile injectable contract development and manufacturing organization formed following the divestiture of Baxter International's BioPharma Solutions business. He was appointed CEO in 2023 by Advent International and Warburg Pincus to lead the business as an independent, private-equity-backed CDMO focused on clinical-to-commercial parenteral manufacturing. Franco is an industry veteran with nearly 30 years of pharmaceutical and biopharmaceutical experience, bringing deep expertise across sterile manufacturing, commercial operations, and global supply chain leadership. Prior to joining Simtra, he served as Chief Executive Officer of ApiJect Systems America, a medical technology company focused on advanced drug-delivery and injection systems. Earlier in his career, he held senior executive roles at Thermo Fisher Scientific, where he served as President of Commercial Operations, and at Patheon Pharmaceuticals, where he was President of Development and Commercial Operations, North America, playing a key role in scaling Patheon's CDMO platform prior to its $7.2 billion acquisition by Thermo Fisher in 2017.   Franco has also held leadership positions at several major pharmaceutical companies, including Vice President of Manufacturing and Supply at Valeant Pharmaceuticals, Global Vice President within Novartis' Consumer Health division, and Site General Manager at McNeil Consumer Healthcare.   Across these roles, he developed a reputation for operational excellence, customer-centric leadership, and the ability to lead complex manufacturing organizations through periods of transformation and growth. As CEO of Simtra, Franco is leading the company through its next phase of expansion, focused on strengthening its sterile fill-finish capabilities, advancing technical differentiation, and investing in capacity to support increasing demand for injectable biologics, vaccines, and complex parenteral products   Molecule to Market is also sponsored by Bora Pharmaceuticals, and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating!

From accidental quality professional to global quality leader - Valerie Brown's story is one of courage, curiosity, and conviction.In today's episode I was joined by Valerie Brown, Head of Global Quality Assurance and Compliance at Thermo Fisher Scientific's Clinical Research Group.I really wanted to speak to Valerie because she brings something different to the quality leadership conversation. Yes, she has held senior quality roles across innovator companies, CDMOs, and now one of the largest CROs in the world. But what makes her story compelling is how she got there - and what she learned along the way.Valerie didn't plan to work in quality. At 22, she was asked to be a scribe for an FDA inspection. The host fell ill on the day. She stepped in - no preparation, no safety net - and handled it.Someone told her she had a knack for it. She wasn't sure she agreed. She still wanted to be in the lab, in manufacturing, doing what she knew. But that moment planted a seed.What followed was a career that took her across CDMOs, innovator companies including Gilead Sciences, and now Thermo Fisher - where she leads global quality assurance and compliance for the clinical research group. She has sat on both sides of the table, as sponsor and as service provider, and that experience shapes everything about how she leads.We talk about the following:How Valerie accidentally became a quality professional, and why that unplanned start shaped everything that followedWhat it felt like to host an FDA inspection at 22, with no preparation and no safety netHer philosophy of servant leadership and what it really means to lead with empathy in a regulated environmentThe challenge of transforming a fragmented quality organisation into a connected, strategic function at Thermo FisherThe difference between working on the innovator side versus the CRO side - and the unique skill set the latter demandsWhy speed and quality are not in conflict, and how embedding quality by design from the outset actually accelerates deliveryHer approach to talent development - why she prefers to grow leaders from within and how she identifies that potential earlyThe growing importance of AI and digital governance in regulated environments, and why quality professionals need to engage with these tools nowWhat keeps her up at night heading into 2026 - from talent gaps to trial complexity to the pace of regulatory changeThe advice she would give her younger self, and what she believes every aspiring quality leader needs to understandValerie Brown is a highly accomplished global quality leader whose career is a masterclass in adaptability, influence, and patient-centric thinking. She leads with purpose, develops people with intention, and approaches every challenge with the mindset of a problem solver - exactly the kind of leader our industry needs more of.Thank you Valerie for sharing your incredible journey. Hope everyone enjoys the show!

In this episode, we examine Thermo Fisher Scientific as a case study in modern biotech infrastructure and crisis response capability. The discussion explores the company's reach across laboratory tools, genetic data technologies, distribution networks, clinical execution, and pharmaceutical manufacturing, along with documented pandemic-era participation and expansion through acquisition. The episode also considers ethical concerns surrounding biological data technologies and surveillance applications, focusing on observable structure and incentives rather than speculation.These developments are viewed through a spiritual lens, asking how believers should respond to increasingly complex institutional systems intersecting with identity, commerce, and governance. The closing segment incorporates reflections from Pastor Chuck Baldwin's February 8, 2026 sermon, “Evangelicals' Divine Litmus Test,” connecting themes of discernment and spiritual allegiance with the investigative discussion.Email: thefacthunter@mail.comEvangelicals' Divine Litmus Test - 2/8/26 By Pastor Chuck Baldwin https://youtu.be/bgNLeTTXHC0?si=UTbHmjhRO6rCqzEb Give to Liberty Fellowship https://libertyfellowshipmt.com/Donate.aspxChuck Baldwin's Website: https://chuckbaldwinlive.com

Grâce à une fiscalité avantageuse, l'Irlande a su attirer les géants pharmaceutiques, au point d'en faire l'un des piliers de son économie. Mais Donald Trump brandit désormais la menace de droits de douane, pour pousser ces entreprises à relocaliser aux Etats-Unis. Or, les médicaments représentent près de la moitié des exportations irlandaises, avec les États-Unis comme premier client ! En Europe, l'Irlande serait ainsi le pays le plus exposé. Près de Cork, Ringaskiddy, surnommé le « village du Viagra », retient son souffle. Reportage de Clémence Pénard. John n'avait que 22 ans quand Pfizer s'est installé à Ringaskiddy. C'était en 1969 : « Tu vois, juste là, le château d'eau ? L'espèce de champignon, là ! Ça appartient à Pfizer !  » Le succès est tel que l'entreprise s'empresse de construire deux autres usines. Si bien qu'aujourd'hui, sous les coups de 8 heures, le site devient une véritable fourmilière : « Le matin, les routes sont totalement saturées : les files de voitures s'étendent sur des kilomètres. Et c'est la même chose le soir ! Une autoroute devait être construite il y a trente ans… Bon, elle doit être terminée d'ici trois ans. On vit dans l'espoir ! » Le « Pfizer Stop » Un arrêt de bus, le « Pfizer Stop », a tout de même été créé, rien que pour les salariés qui produisent, depuis 1998, le médicament le plus tonique de la région : le viagra !  « À l'époque, on n'arrivait même pas à prononcer le nom : "Pf i zeur" ! Mais tout le monde voulait y travailler, absolument tout le monde. Les salaires étaient multipliés par quatre ! Même le fournisseur de papier toilette était devenu riche ! » Et il n'a pas fallu longtemps pour que le « village du Viagra » attire d'autres géants pharmaceutiques. Aujourd'hui, les Américains Johnson & Johnson, Thermo Fisher ou encore BioMarin profitent eux aussi du port de cet ancien village de pêcheurs, idéal pour exporter leurs médicaments !  Et à seulement 20 km de là, Lilly fabrique Mounjaro et Zepbound, deux médicaments anti-obésité, best-sellers aux États-Unis !  Ambiance à Ringaskiddy et dans les villages voisins Ainsi, dans Ringaskiddy et les villages voisins, ce sont plus de 20 000 personnes qui travaillent pour ces mastodontes, souvent de génération en génération. Audrey Buckley est élue locale du Fianna Fáil, le parti au pouvoir : « S'il arrivait quoi que ce soit à l'industrie pharmaceutique ici, ce serait tout simplement dévastateur pour toute la région. Dévastateur… Aujourd'hui, au dîner autour de la table, les mêmes questions reviennent sans cesse : est-ce que tels travaux ont démarré à l'usine? Est-ce qu'il y a de nouveaux projets ? Or, tout semble à l'arrêt. C'est une énorme source d'angoisse, les gens repoussent l'achat d'une voiture, l'extension de la maison, et ainsi de suite. Ils dépensent moins, c'est sûr, donc on voit déjà des effets ! »  Économiste à l'université de Cork, Eleanor Doyle voit aussi un ralentissement du secteur, mais tente tout de même de rassurer : « Pour les usines pharmaceutiques, les délais pour obtenir les autorisations de construction sont si longs, qu'à moyen terme, une délocalisation est peu envisageable ! » Pour l'instant, l'Irlande profite d'un répit, l'administration américaine semblant se concentrer sur d'autres régions du monde.

Grâce à une fiscalité avantageuse, l'Irlande a su attirer les géants pharmaceutiques, au point d'en faire l'un des piliers de son économie. Mais Donald Trump brandit désormais la menace de droits de douane, pour pousser ces entreprises à relocaliser aux Etats-Unis. Or, les médicaments représentent près de la moitié des exportations irlandaises, avec les États-Unis comme premier client ! En Europe, l'Irlande serait ainsi le pays le plus exposé. Près de Cork, Ringaskiddy, surnommé le « village du Viagra », retient son souffle. Reportage de Clémence Pénard. John n'avait que 22 ans quand Pfizer s'est installé à Ringaskiddy. C'était en 1969 : « Tu vois, juste là, le château d'eau ? L'espèce de champignon, là ! Ça appartient à Pfizer !  » Le succès est tel que l'entreprise s'empresse de construire deux autres usines. Si bien qu'aujourd'hui, sous les coups de 8 heures, le site devient une véritable fourmilière : « Le matin, les routes sont totalement saturées : les files de voitures s'étendent sur des kilomètres. Et c'est la même chose le soir ! Une autoroute devait être construite il y a trente ans… Bon, elle doit être terminée d'ici trois ans. On vit dans l'espoir ! » Le « Pfizer Stop » Un arrêt de bus, le « Pfizer Stop », a tout de même été créé, rien que pour les salariés qui produisent, depuis 1998, le médicament le plus tonique de la région : le viagra !  « À l'époque, on n'arrivait même pas à prononcer le nom : "Pf i zeur" ! Mais tout le monde voulait y travailler, absolument tout le monde. Les salaires étaient multipliés par quatre ! Même le fournisseur de papier toilette était devenu riche ! » Et il n'a pas fallu longtemps pour que le « village du Viagra » attire d'autres géants pharmaceutiques. Aujourd'hui, les Américains Johnson & Johnson, Thermo Fisher ou encore BioMarin profitent eux aussi du port de cet ancien village de pêcheurs, idéal pour exporter leurs médicaments !  Et à seulement 20 km de là, Lilly fabrique Mounjaro et Zepbound, deux médicaments anti-obésité, best-sellers aux États-Unis !  Ambiance à Ringaskiddy et dans les villages voisins Ainsi, dans Ringaskiddy et les villages voisins, ce sont plus de 20 000 personnes qui travaillent pour ces mastodontes, souvent de génération en génération. Audrey Buckley est élue locale du Fianna Fáil, le parti au pouvoir : « S'il arrivait quoi que ce soit à l'industrie pharmaceutique ici, ce serait tout simplement dévastateur pour toute la région. Dévastateur… Aujourd'hui, au dîner autour de la table, les mêmes questions reviennent sans cesse : est-ce que tels travaux ont démarré à l'usine? Est-ce qu'il y a de nouveaux projets ? Or, tout semble à l'arrêt. C'est une énorme source d'angoisse, les gens repoussent l'achat d'une voiture, l'extension de la maison, et ainsi de suite. Ils dépensent moins, c'est sûr, donc on voit déjà des effets ! »  Économiste à l'université de Cork, Eleanor Doyle voit aussi un ralentissement du secteur, mais tente tout de même de rassurer : « Pour les usines pharmaceutiques, les délais pour obtenir les autorisations de construction sont si longs, qu'à moyen terme, une délocalisation est peu envisageable ! » Pour l'instant, l'Irlande profite d'un répit, l'administration américaine semblant se concentrer sur d'autres régions du monde.

In der heutigen Folge sprechen die Finanzjournalisten Anja Ettel und Holger Zschäpitz über einen Ritterschlag für Intel, Rebound bei Rüstung und einen Branchen-Deal der Superlative. Außerdem geht es um Apple, Garmin, Thermo Fisher, Boston Scientific, Johnson Health Tech, Planet Fitness, Life Time, Gym Group, Basic Fit, Xponential Fitness, Technogym, Nike, Adidas, Puma, Lululemon, Lockheed Martin, L3Harris, Kratos Defense, Nvidia, Oracle, Apple, Palantir, Bayer, Puma, Tilray Brands, General Motors, Elevance Health, Centene, Cigna, UnitedHealth und Molina Healthcare, Rio Tinto, Glencore, BHP Group, Siemens, Meta und Keller Group. Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Der Börsen-Podcast Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

In this conversation, we pull back the curtain on alpha-gal syndrome diagnostic testing at Thermo Fisher Scientific with Gary Falcetano, PA-C. Gary shares insights into how the alpha-gal syndrome test works and answers some of our most frequently asked questions. How do you talk to your provider about being tested? Is the test covered by insurance? What provider can order the test? He also dives into how Allergy Insider, Thermo Fisher's patient resource, is bringing alpha-gal into the conversation. Tune in now to learn more! Gary Falcetano, PA-C, serves as Senior Manager Global Medical and Scientific Affairs for allergy at Thermo Fisher Scientific. Gary has been a Board Certified Physician Assistant for over 28 years, and is the host of Allergy Insider's ImmunoCAST podcast.Visit Allergy Insider to learn more about their patient resources and be sure to follow on social media: @allergyinsider

In this episode of Data in Biotech, host Ross Katz sits down with John Liberty, Senior Bioanalysis Technical Sales Consultant at Thermo Fisher Scientific. They dive deep into how Watson LIMS™ supports regulated bioanalysis workflows, the evolving role of lab automation, and how Connect Enterprise aims to unify biotech digital ecosystems. What you'll learn in this episode: >> Why Watson LIMS is purpose-built for bioanalysis and how it enhances compliance and data traceability. >> The role of lab automation in boosting productivity and reducing manual tasks. >> How Connect Enterprise integrates lab systems across vendors into a seamless workflow.  >> Key considerations for implementing LIMS in startup versus established biotech environments. >> The ROI of digital lab solutions in supporting scalable, compliant biotech operations. Meet Our Guests John Liberty is a GMP-trained scientist with a strong focus on ELISA method development, validation, and transfer. He pairs his hands-on scientific background with experience in project management, CRO coordination, data analysis, and training, making him someone who really understands how work moves from the lab bench to real-world application. John has also spent time on the product and customer side, doing technical sales and demos for Watson LIMS™ software, giving him a rare blend of technical depth and communication skills. About The Host Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with Our Guest: Sponsor: CorrDyn, a data consultancyConnect with John Liberty  on LinkedIn  Connect with Us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!Connect with Ross Katz on LinkedIn Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn.

In this Mol Bio Minutes episode, Thermo Fisher Scientific's Monika Jazdauskaitė dives into the versatile world of Recombinase Polymerase Amplification (RPA). Unlike PCR, RPA operates at a constant, low temperature (around 37–42°C), enabling fast, equipment-light workflows that are ideal for field diagnostics and decentralized labs. Monika explains how the method works and why RPA is emerging as a go-to technique for both DNA and RNA target detection.She highlights RPA's specificity, sensitivity, and robustness against common inhibitors like ethanol and heparin, critical for applications like respiratory pathogen detection or low-quality sample inputs. Plus, she shares how RPA's gentle conditions and lyophilization compatibility make it a strong candidate for stabilizing next-generation sequencing (NGS) libraries, especially those with high GC content.Whether you're looking to simplify pathogen detection or streamline your sequencing prep, RPA offers a compelling alternative to traditional amplification. And with ready-to-use kits like the Invitrogen™ Lyo-ready RPA Kit, Thermo Fisher is helping researchers bring speed and stability to molecular workflows, all with no thermal cycler required. Subscribe to get future episodes as they drop and if you like what you're hearing we hope you'll share a review or recommend the series to a colleague.  Visit the Invitrogen School of Molecular Biology to access helpful molecular biology resources and educational content, and please share this resource with anyone you know working in molecular biology. For Research Use Only. Not for use in diagnostic procedures.

“The differentiator in our business isn't the equipment and the facility—it's the scientists working with customers to create assays and solve complex scientific challenges.”Leon Wyszkowski has spent nearly three decades in drug development, including 20 years at Thermo Fisher Scientific in roles spanning clinical services, CDMO operations, and now analytical services. His perspective on the evolution from internal pharma operations to service provider offers insights into how the industry's approach to outsourcing has matured.In this conversation, Leon discusses Thermo Fisher's expansion in the Nordics, the company's partnership with AstraZeneca's BioVenture Hub, and why trust remains the fundamental factor when biotechs and pharma companies evaluate analytical service partners.Read more.

Rafael Ojeda, miembro del Comité de Inversiones de Ursus 3 Capital Agencia de Valores, analiza las claves en el mercado norteamericano: Verizon, Caterpillar, Boeing, Kraft-Heinz, Nvidia, Microsoft, Alphabet, Meta y Thermo Fisher.

US President Trump said he will discuss a lot of things with Chinese President Xi in two weeks; however, he added that the meeting might not happenUS futures are marginally firmer, while European futures point to a slightly lower cash openDXY softened overnight, EUR and GBP lifted modestly off Tuesday's trough, USD/JPY contained and back below 152.00Fixed benchmarks rangebound into supplyCrude underpinned by a Russian strike on Ukrainian energy infrastructure, XAU continued to falter to the USD 4k/oz mark but has since bouncedLooking ahead, highlights include UK CPI (Sep), CCP 4th Plenum (20th-23rd), BoJ SLOOS, Speakers including ECB's de Guindos, Lagarde & Fed's Barr, Supply from Germany & US, Earnings from SAP, Barclays, Akzo Nobel, Tesla, IBM, Kinder Morgan, Alcoa, Lam Research, GE Vernova, Hilton, AT&T & Thermo Fisher.Click for the Newsquawk Week Ahead.Read the full report covering Equities, Forex, Fixed Income, Commodites and more on Newsquawk

European bourses are broadly lower, but FTSE 100 outperforms after UK inflation; US equity futures are modestly weaker.USD is flat & GBP hit after region's softer-than-expected inflation report, which has boosted bets for a cut in December.USTs are flat/slightly firmer ahead of supply, Gilts gap higher after CPI, Bunds marginally pressured after yet another poor auction.Initial morning bounce back in gold has faded with XAU now lower on the session; crude complex is on a firmer footing.Looking ahead, CCP 4th Plenum (20th-23rd), Speakers including ECB's de Guindos, Lagarde & Fed's Barr, Supply from the US, Earnings from SAP, Tesla, IBM, Kinder Morgan, Alcoa, Lam Research, GE Vernova, Hilton, AT&T & Thermo Fisher.Read the full report covering Equities, Forex, Fixed Income, Commodites and more on Newsquawk

Imagine waking up to find your company's most valuable IP leaked—not by hackers, but by the very AI tools you trusted.This isn't a distant scenario; it's happening inside pharma and biotech right now.And the cost isn't just financial—it's patient lives, broken trust, and an industry on the edge of losing credibility. In this episode, Kat Kozyrytska shares how leaders can act before invisible risks become catastrophic. From her personal journey in post-Soviet Ukraine to building frameworks in global biotech, Kat reveals why “yesterday problems” with AI demand urgent attention today.You'll learn how data privacy failures propagate quietly, why embedding organizational values into AI is essential, and how collaboration across companies can safeguard innovation and accelerate therapies. The future of biotech won't be secured by hype or speed—but by trust, ethics, and the courage to act before it's too late. 

In der heutigen Folge sprechen die Finanzjournalisten Anja Ettel und Holger Zschäpitz über einen Gamechanger-Deal, Wall-Street-Rekorde trotz Shutdown und das fulminante Börsendebüt von Fermi. Außerdem geht es um Pfizer, Merck, Eli Lilly, Novo Nordisk, Vertex, Regeneron, Thermo Fisher, Repligen, Danaher, Boston Scientific, Abbott, Intuitive Surgical, Bayer, Merck, Salzgitter, Thyssenkrupp, Bitcoin, Solana, Ether, Sartorius, Palantir Technologies, Thales, L3Harris Technologies, RTX, Kratos Defense & Security Solutions, AeroVironment, DroneShield, Elbit Systems, Electro Optic Systems, Saab AB, Hensoldt, Mercury Systems, QinetiQ, Chemring Group, Cohort, Exail Technologies, Rocket Lab, Iridium Communications, BlackSky Technology, Electro Optic Systems, Leidos Holdings, CACI International, Parsons, Telos Corp, Leidos, SAIC, QinetiQ, Parsons VanEck Space Innovators ETF (WKN: A3DP9J), Invesco Defence Innovation ETF (WKN: A40J95), Global X Defence Tech ETF (WKN: A40E7A), Droneshield, Palantir, Red Cat Holdings. Wir freuen uns über Feedback an aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Der Börsen-Podcast Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article104636888/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

In this episode of Speaking of Mol Bio, host Steve Lewis speaks with Dr. Melissa Wu, co-founder and CEO of Seeding Labs, a nonprofit that's redefining global scientific access. Dr. Wu shares the inspiring story of how Seeding Labs helps institutions in developing nations build research infrastructure by redistributing surplus laboratory equipment from partners like Thermo Fisher Scientific.With an innovative model that connects equipment donors in the global North with universities and institutes across Africa, Asia, and Latin America, Seeding Labs enables groundbreaking science in places where opportunity is limited but talent is abundant. Dr. Wu highlights examples like the Malawi University of Science and Technology, whose graduates are now staffing the country's first hospital microbiology labs, and a Beninese research team using donated PCR equipment to improve the yield of indigenous crops like the miracle berry.More than a logistics operation, Seeding Labs is also fostering scientific networks, reversing brain drain, and giving researchers confidence, courage, and agency. Dr. Wu offers a compelling vision of an equitable global scientific ecosystem, and shares how listeners can get involved—whether by donating equipment, funds, or simply spreading the word. Subscribe to get future episodes as they drop and if you like what you're hearing we hope you'll share a review or recommend the series to a colleague.  Visit the Invitrogen School of Molecular Biology to access helpful molecular biology resources and educational content, and please share this resource with anyone you know working in molecular biology. For Research Use Only. Not for use in diagnostic procedures.

Edwin Gonzalez shares his journey from a BioBuilder apprentice to becoming a lead scientific support specialist at Thermo Fisher by age 23, highlighting how hands-on experiences and mentorship shaped his career path.• Middle school science teacher sparked Edwin's interest in science through engaging projects and supportive environment• First in his family to pursue science, without STEM role models at home• Joined BioBuilder apprenticeship program in 2019 after learning about it from a classmate• Gained first hands-on lab experience learning aseptic technique, pipetting, PCR, and bacterial transformation• Worked on biodesign project to create a device detecting airborne allergens• BioBuilder experience helped him decide to major in biology at Suffolk University• Skills learned at BioBuilder created foundation that made college coursework easier• Landed first industry position at Novo Nordisk through connections from a LabCentral internship• Currently works at Thermo Fisher as a lead scientific support specialist• Role combines lab operations, facilities management and direct research support• Recommends exploring multiple aspects of biology to build a diverse toolkit of experiencesLearn more about BioBuilder's programs for students, educators, and industry professionals here

Dr. Barbara Paldus' insights will challenge everything you thought you knew, and her captivating warmth will make you forget she's a trailblazing entrepreneur and renowned scientist in biotechnology and skincare. With a Ph.D. from Stanford, her passion for innovation is matched only by her mission to enhance lives. She began her founder journey at Picarro, inventing a leading greenhouse gas detection system, then at Finesse Solutions (acquired by Thermo Fisher), advancing biotech equipment for vaccine production, ultimately finding herself on the other side of two successful exits, holding over 50 U.S. patents. In 2018, driven by her son's severe allergies to mainstream skincare products, she founded Codex Labs, developing biotech plant-based solutions for nearly every skin condition. Now, she is using everything she's learned to launch the first-ever Dermatology telehealth platform, bringing quality, all-inclusive skincare right to your front door. In this episode, Dr. Paldus shares her deep insights into the importance of keeping your skin microbiome healthy, and how it ties in with the gut and the brain, and talks about her line of products that help with skin issues and more. RESOURCES: Learn more about Dr. Paldus here: https://www.codexlabscorp.com/ Instagram: @codexlabs Get 15% off Peluva minimalist shoe with coupon code COACHTARA here: http://peluva.com/coachtara   CHAPTERS: 0:00 Intro 4:15 Personal story of how Dr. Paldus got into the skin & gut microbiome 11:15 Skin microbiome 20:42 What can you do about eczema? 37:42 How Dr. Paldus' products can help 47:00 Mindset shift from impostor syndrome to diving in 51:18 Where to get Dr. Paldus' products WORK WITH ME: Are You Looking for Help on Your Wellness Journey? Here's how I can help you: TRY COACH TARA APP FOR FREE: http://taragarrison.com/app LEVEL UP PROGRAM: http://taragarrison.com/level-up INDIVIDUAL ONLINE COACHING: https://www.taragarrison.com/work-with-me CHECK OUT HIGHER RETREATS: https://www.taragarrison.com/retreats   SOCIAL MEDIA:  Instagram @coachtaragarrison TikTok @coachtaragarrison Facebook @coachtaragarrison Pinterest @coachtaragarrison   INSIDE OUT HEALTH PODCAST SPECIAL OFFERS: ☑️ Upgraded Formulas Hair Test Kit Special Offer: https://bit.ly/3YdMn4Z ☑️ Upgraded Formulas - Get 15% OFF Everything with Coupon Code INSIDEOUT15: https://upgradedformulas.com/INSIDEOUT15 ☑️ Rep Provisions: Vote for the future of food with your dollar! And enjoy a 15% discount while you're at it with Coupon Code COACHTARA: https://bit.ly/3dD4ZSv   If you loved this episode, please leave a review! Here's how to do it on Apple Podcasts: Go to Inside Out Health Podcast page: https://podcasts.apple.com/us/podcast/inside-out-health-with-coach-tara-garrison/id1468368093 Scroll down to the ‘Ratings & Reviews' section. Tap ‘Write a Review' (you may be prompted to log in with your Apple ID). Thank you!

BOOTCAMP: Estructuras de Mercado - Rangos, Breakouts y Volatilidad: domina la dinámica real del precio. Mas info sobre el curso Aquí!

Stephen Grootes speaks to Marcin Kouri, Senior Director of Thermo Fisher Scientific for EMEA, about the launch of SA’s first cutting-edge science training hub and its mission to power local innovation and health breakthroughs. The Money Show is a podcast hosted by well-known journalist and radio presenter, Stephen Grootes. He explores the latest economic trends, business developments, investment opportunities, and personal finance strategies. Each episode features engaging conversations with top newsmakers, industry experts, financial advisors, entrepreneurs, and politicians, offering you thought-provoking insights to navigate the ever-changing financial landscape. Thank you for listening to a podcast from The Money Show Listen live Primedia+ weekdays from 18:00 and 20:00 (SA Time) to The Money Show with Stephen Grootes broadcast on 702 https://buff.ly/gk3y0Kj and CapeTalk https://buff.ly/NnFM3Nk For more from the show, go to https://buff.ly/7QpH0jY or find all the catch-up podcasts here https://buff.ly/PlhvUVe Subscribe to The Money Show Daily Newsletter and the Weekly Business Wrap here https://buff.ly/v5mfetc The Money Show is brought to you by Absa Follow us on social media 702 on Facebook: https://www.facebook.com/TalkRadio702702 on TikTok: https://www.tiktok.com/@talkradio702702 on Instagram: https://www.instagram.com/talkradio702/702 on X: https://x.com/CapeTalk702 on YouTube: https://www.youtube.com/@radio702 CapeTalk on Facebook: https://www.facebook.com/CapeTalkCapeTalk on TikTok: https://www.tiktok.com/@capetalkCapeTalk on Instagram: https://www.instagram.com/CapeTalk on X: https://x.com/Radio702CapeTalk on YouTube: https://www.youtube.com/@CapeTalk567See omnystudio.com/listener for privacy information.

988: In this episode of Technovation, we feature a panel from the Metis Strategy Summit moderated by Metis Strategy's Co-Head of Executive Networks, Media, and Research Steven Norton, exploring how senior technology executives are aligning AI to their business strategy. Joining the conversation are Ryan Snyder, CIO of Thermo Fisher Scientific; Ramkumar Rayapureddy, CIO of Viatris; and Allen Fazio, CIO of Houlihan Lokey. Together, they share how their organizations are evolving from isolated AI pilots to holistic strategies grounded in business value, robust governance, and relentless data modernization. The panelists discuss the practical realities of establishing clear measurement frameworks, navigating the tension between centralized control and decentralized innovation, and leading cultural change as AI adoption accelerates across regulated and fast-moving industries.

Welcome to this new episode of Beyond the Thesis with Papa PhD! In this episode, host David Mendes sits down with Morgan Foret, who brings a fresh perspective on navigating the journey from academia to industry. Morgan shares her personal story, beginning with her undergraduate studies in cell biology, an international research internship in Germany, and her PhD in pharmacology at McGill University, where she focused on Alzheimer's disease. Now working in regulatory affairs at Thermo Fisher, Morgan discusses the realities and misconceptions of moving into industry after a PhD. Together, David and Morgan unpack the challenges she faced and the transferable skills and career strategies that helped her smoothly transition out of academia and into regulatory affairs.   Morgan Foret's journey in science began at the University of Calgary, where she earned her undergraduate degree in cell biology. Driven by curiosity, Morgan spent a year on academic exchange at Lund University in Sweden, conducting undergraduate research that expanded her international perspective. Back in Calgary, she explored the world of nanoparticles and lung cells, gaining hands-on experience using an atomic force microscope, a time she remembers fondly for the engaging research and the thrill of discovery. After graduation, Morgan pursued an industry internship in Germany through the DAAD RISE Professional program, spending three months at Merck in Darmstadt. There, she crossed into the world of industrial research, getting a firsthand look at how scientific discoveries move from lab to industry. Throughout her journey, Morgan has combined academic excellence, international experience, and research initiative, shaping her as a promising and well-rounded scientist. What we covered in the interview: Embrace Hands-On Industry Experience Early: Programs like the DAAD RISE internship in Germany or organizing/attending industry networking events during your studies are game-changers, helping you understand how your research background can translate to industry roles and widen your global perspective. Leverage Transferable Skills, Not Just Your Title: Don't underestimate the power of skills honed during your academic journey—project management, communication, collaboration, and resilience. Learn to highlight these when applying for roles, even if your previous title doesn't match the new one exactly.  Stay Curious & Build Your “Organic” Network: Networking doesn't have to be intimidating or formal. Reach out to peers a year or two ahead of you, connect with alumni, or even organize your own events. Be guided by curiosity; those casual conversations can open doors and demystify the industry landscape. Whether you're considering a move to industry or just want to understand what really happens after the PhD, this episode is packed with practical advice, personal anecdotes, and inspiration. See the resources section below for Morgan Foret's links! This episode's resources: RAPS Quebec Local Networking Group| linkedin.com/showcase/raps-quebec-local-networking-group PCSN (Pharmaceutical Career Student Network, student group at McGill) | linkedin.com/company/pcsn-mcgill Women in Bio Montreal Chapter | linkedin.com/showcase/wib-greater-montreal Women Leaders in Pharma | linkedin.com/company/women-leaders-in-pharma Healthcare Business Women's Association | linkedin.com/showcase/hba-canada-region Thank you, Morgan Foret! If you enjoyed this conversation with Morgan, let her know by clicking the link below and leaving her a message on Linkedin: Send Morgan Foret a thank you message on Linkedin! Click here to share your key take-away from this interview with David! Leave a review on Podchaser ! Support the show !   You might also like the following episodes: Sarah McLusky – Research Adjacent Podcast Collab Colleen Kelley – Unlocking Science Literacy Before University Rayana Luna –Navigating Medical Affairs Careers Sylvie Lahaie – Navigating Stress and Anxiety in Graduate School

Sustainability in the lab isn't just a trend—it's a responsibility. In this quick but powerful Mol Bio Minutes episode, sustainability expert Sune Lund Sporring shares actionable tips to reduce energy use, manage lab waste, and transition to greener materials like Thermo Fisher's Sustain Series bio-based plastics.Discover the difference between bio-based and biodegradable, why second-generation feedstocks are a game-changer, and how to make low-impact changes without compromising performance. Learn how small shifts—like using aluminum beads instead of water in a bath or switching to carbon-reduced plastics—can significantly cut your lab's carbon footprint. And remember: if greener options aren't available, your demand can help shape the market.Helpful resource links mentioned in this episode:My Green Lab – Facts and resources about lab sustainabilityEnergy use of fume hoods – Energy use and savings ideas for fume hoodsGreener by Design – Thermo Fisher's approach to green solutionsLab Armor™ Beads – A sustainable option to replace water in water bathsInstrument trade up program – trade in your equipment to be green and give it a second lifeLab plastic waste – Stats about plastic waste in labsDoing something about it – Thermo Fisher's lower carbon plastics solutionSustain Series PCR plastics – Lower carbon footprint, without workflow interruptionReasons to believe – Fact sheet about Sustain Series PCR plastics Subscribe to get future episodes as they drop and if you like what you're hearing we hope you'll share a review or recommend the series to a colleague.  Visit the Invitrogen School of Molecular Biology to access helpful molecular biology resources and educational content, and please share this resource with anyone you know working in molecular biology. For Research Use Only. Not for use in diagnostic procedures.

The good — Thermo Fisher opens center to boost cell therapy development The bad — FDA cites Aurobindo plant after Raleigh inspection The ugly — Trump probes pharma imports as tariff threat looms

In this episode of Technovation, host Peter High speaks with Ryan Snyder, Senior VP & CIO of Thermo Fisher Scientific, a $40 billion global leader in life sciences. Ryan shares how AI, automation, and data strategy are driving digital transformation—optimizing operations, accelerating clinical trials, and enhancing customer experiences.

As the organ transplant list continues to grow, experts in the transplant diagnostics industry are looking for ways to address the supply and demand challenges within the field. New tactics, like retransplantation and xenotransplantation, and new testing methods, such as HLA testing and transplant diagnostics, are being explored to boost transplant success rates and ensure more patients get the lifesaving transplants they need. As President of Thermo Fisher Scientific's transplant diagnostics division, Tina Liedtky is at the cutting edge of meeting this challenge. She's also passionate about addressing health equity issues, such as ingrained biases regarding gender and race, to help bridge the transplantation gap.Tina joined Meg for a fascinating discussion about the future of transplantation, closing 'the gap', and Thermo Fisher's recent award. Qualio website:https://www.qualio.com/ Previous episodes:https://www.qualio.com/from-lab-to-launch-podcast Apply to be on the show:https://forms.gle/uUH2YtCFxJHrVGeL8 Music by keldez

Nicholas Capman of The FDA Group welcomes David Festa, Director of Corporate Quality at Thermo Fisher Scientific, to explore whether pharmaceutical and medical device companies are auditing suppliers too frequently and with the right personnel.With over 25 years of experience in quality management and oversight of tens of thousands of suppliers, David advocates for a more strategic approach that balances quality, compliance, and business needs through "exception-based" auditing.Rather than rigidly adhering to calendar-based audit schedules, David suggests companies should assess suppliers based on performance metrics, risk factors, and the criticality of materials they provide. He challenges the industry norm that every supplier must be visited at predetermined intervals, arguing that well-performing suppliers with stable processes may not require frequent on-site visits.David emphasizes the importance of matching auditor expertise with supplier categories. For example, an auditor with deep knowledge of plastics manufacturing will provide far more valuable insights when evaluating a plastics supplier than someone familiar only with general standards. This targeted approach has helped Thermo Fisher predict quality issues and decrease the percentage of poor-performing suppliers.The conversation explores how post-pandemic practices have evolved, with companies developing more harmonized approaches to global auditing and implementing centralized audit portals. David also introduces the concept of a "supplier pricing index" that quantifies the true cost of poor quality, providing a more accurate picture of supplier value than piece price alone.While ISO certifications provide a foundation for quality systems, David cautions against over-reliance on certifications or imposing unnecessary standards on suppliers. The most effective approach focuses on whether suppliers can maintain control of their manufacturing processes and consistently deliver quality products, regardless of certification status.For companies looking to optimize their supplier quality programs, the key is putting the right people in the right places, implementing quantifiable metrics, and taking a holistic view that integrates quality with other business functions.____The FDA Group helps life science organizations rapidly access the industry's best consultants, contractors, and candidates. Our resources assist in every stage of the product lifecycle, from clinical development to commercialization, with a focus in Quality Assurance, Regulatory Affairs, and Clinical Operations. For project or resource needs, visit: ⁠⁠⁠⁠⁠⁠thefdagroup.com⁠⁠⁠⁠⁠⁠.

How to Build Lasting Customer Relationships and Boost Growth Christoph Senn and Mehak Gandhi propose that B2B companies rethink their growth logic in their recent book Triple Fit Strategy. They lay out the Triple Fit Strategy framework to help companies escape the product-centric mindset and put customers at the heart of their business strategy. Companies using this framework can contribute 10x more to their customers' success and potentially double account values in less than three years. Summary of Triple Fit Strategy Senn and Gandhi suggest a bold new way of doing business that shifts the focus from traditional product selling to a fully customer-centric approach. Their Triple Fit Strategy challenges the old "us and them" mentality, encouraging suppliers and customers to collaborate as if they were a single entity. The result? Businesses that grow far beyond what either party could achieve alone. One Company? At its core, the Triple Fit Strategy puts customers at the centre of three critical areas: planning, execution, and resources. The strategy revolves around a simple and powerful question: What if we - supplier and customer - were one company? Drawing on over two decades of research, the authors argue that companies adopting this framework can contribute ten times more to their customers' success while doubling account values in under three years. Proven Results This isn't just theory. The book shares lessons from global giants like BASF, GE, Microsoft, and Danish shipping leader Maersk, which used the strategy to unlock hundreds of millions of dollars in new opportunities with a New Zealand partner. Backed by a database of over 10,000 cases, the Triple Fit Strategy offers practical tools to bring customers into your company's internal processes, helping to redefine customer relationships, allocate resources wisely, and achieve faster, more meaningful breakthroughs. Business cases The book includes real-life business cases from 3M, Agrana, BASF, Best Buy, BMW, Danone, db Audio, DSM, Evonik, Hillebrand Gori, Indicia, Konica Minolta, Maersk, Marriott, MUREX, Natura, P&G, Sonos, Thermo Fisher, Unilever, Vodafone, and WMF/Schaerer. For Companies Without Large Budgets? Senn and Gandhi outline three practical steps for businesses without a large budget for external consultancy: 1. Create a total business view by analysing business relationships within the Triple Fit canvas. 2. Understand internal politics and identify which stakeholders on both sides will support your case. 3. Foster a mindset of strategic alignment between supplier and customer. For businesses ready to step away from the "product-first" mindset, this book is a game-changer. See more about the book here. About the Authors Christoph Senn Christoph is Adjunct Professor of Marketing at INSEAD and founder/CEO of Valuecreator, a global provider of B2B growth tools and programs. He has taught at leading institutions such as Columbia Business School and the University of St. Gallen. His work has been published in journals, including California Management Review and Harvard Business Review. Mehak Gandhi Mehak is Head of Research & Training at Valuecreator, designing B2B growth accelerator programs and sales strategies for global companies. Her experience spans industries, having worked with Allianz, Maersk, Schindler, Thermo Fisher, and others. She applies the Triple Fit tools to achieve strategic alignment and growth for her clients. TRIPLE FIT STRATEGY: How to Build Lasting Customer Relationships and Boost Growth by Christoph Senn and Mehak Gandhi. Published by Harvard Business Press, ISBN No: 9781647827144 Billy Linehan Billy Linehan is an experienced consultant and advisor, currently serving as Partnership Director at Target Integration, where he leads the Business Connector programme. This initiative builds a network of professionals to drive digital transformation and IT solutions across diverse sectors. As the founder of Celtar Advisers, Billy has guided nu...

Recorded at NC Life Sciences Organization's Annual Meeting, Heather and Matthew are joined by John Van Hoy, Executive Director of Data Science & Advanced Analytics at PPD, a subsidiary of Thermo Fisher. John is an innovator in advanced analytics for the healthcare and life sciences industries and discusses how PPD is leveraging AI to enhance clinical research. Tune in for an insightful conversation about the benefits and challenges of using AI in drug development!

Welcome to the Rose Woman Podcast, where we explore the cutting edge of health, wellness, and personal empowerment. Today, we have a very special guest - Dr. Michael Snyder, a leader in the field of functional genomics and proteomics, and one of the major participants of the ENCODE project.He has also combined different state-of-the-art "omics" technologies to perform the first longitudinal detailed integrative personal omics profile (iPOP) of person and used this to assess disease risk and monitor disease states for personalized medicine. Dr. Snyder is the cofounder of Personalis, SensOmics, Qbio @qbioinc, January AI, Filtricine, Mirvie, Protos, Protometrix (now part of Thermo-Fisher). Affomix (now part of Illumina).This is an episode that just might change the way you think about your health and the future of healthcare - don't miss it.In this episode, we cover:Importance of measuring health frequently while people are still healthy to detect early signs of diseaseThe use of wearables, such as smartwatches and Oura rings, plays a crucial role in early detectionBreakdown of omics concepts like genomics, proteomics, and metabolomicsThe role of hormones in aging and the impact of andropause and menopauseEmphasis on the importance of exercise and strength training for overall healthAdvancements in DNA sequencing, mass spectrometry, and wearablesThe importance of continuous data collection and the role of AI in integrating and analyzing large datasetsThe challenges of implementing proactive health monitoring in the current healthcare systemImportance of financial incentives and the role of employers in promoting health and wellnessVision for the future of healthcare with continuous health monitoring and AI-powered personalized recommendationsThe role of hormones and agingHelpful links:Michael Snyder, Ph.D. - Stanford W. Ascherman Professor of Genetics and SnyderlabGenomics and Personalized Medicine: What Everyone Needs to KnowFounder Letter: The New Science on Aging Well by Christine MasonFind Rosebud Woman on Instagram as @rosebudwoman, Christine on Instagram as @christinemariemasonFind Radiant Farms on Instagram @weareradiantfarms Hosted on Acast. See acast.com/privacy for more information.

In this podcast, we spoke with Isha Dey, Senior Scientist, Cell Biology R&D, at Thermo Fisher Scientific about the challenges researchers face in selecting appropriate cell culture conditions due to variability in cell lines, lack of standardized protocols, and inconsistent reagent quality. Thermo Fisher Scientific's new Cell Culture Select Tool was developed to address these challenges by providing specific recommendations for media, FBS, and cultureware for over 150 cell lines, backed by extensive R&D data. Understanding the Challenges in Cell Culture Selection Thermo Fisher Scientific's new Cell Culture Select Tool addresses a persistent challenge in laboratory science: identifying the appropriate cell culture conditions and selecting the right media, supplements, and reagents for different cell lines. The process is complicated by factors like cell line variability, lack of standardized protocols, and inconsistent reagent quality. These issues can introduce variability and impact experimental results, posing a challenge for scientists across labs. “Different cell lines have unique requirements,” explained Isha. “It's challenging to pinpoint optimal culture conditions due to variability in cell line responses. Additionally, there isn't always a standardized protocol across labs or comprehensive information on specific culturing needs. This can make it difficult to select the most appropriate media, supplements, and other materials.” Ensuring a consistent supply of high-quality products is essential for reproducibility in experiments. Thermo Fisher Scientific's trusted brands, such as Gibco, Nunc, and Invitrogen, are known for their quality, which is critical for minimizing variability in experimental readouts. The Inspiration Behind the Cell Culture Select Tool The idea for the Cell Culture Select Tool originated from an update to Thermo Fisher Scientific's online technical reference library. Previously, the website listed recommended media types segmented by cell line culture methods—adherent, semi-adherent, or suspension. While helpful, this list was lengthy and lacked interactive functionality. Isha said, “We realized that we could streamline this information into a user-friendly tool”. “In our R&D labs, we culture over 150 cell lines using various media, supplements, and equipment. By making this data accessible to other researchers through an interactive tool, we hoped to eliminate the guesswork and enable reproducible cell culture success.” The tool now provides recommendations for specific media, supplements, and cultureware for culturing, passaging, and freezing over 150 cell lines. With in-house data supporting 75% of these lines, researchers gain access to the resources and insights gathered from Thermo Fisher's extensive R&D experience. Selecting Cell Lines for the Tool The team started with cell lines listed in their technical reference webpage and expanded the list based on the lines frequently cultured in their R&D labs. These labs conduct heavy cell culture work for various applications, including media development, fluorescence imaging, Western blotting, flow cytometry, transfection, transduction studies, and more. “We wanted to make our R&D data available to researchers for convenience,” shared Isha. “This effort involved many scientists across R&D sites who contributed data and images showing how each cell line appears in recommended media.” Quality and Verification in Thermo Fisher's Labs The tool's data is backed by rigorous testing in Thermo Fisher's R&D labs. Cells are grown in their respective media, culture plastics, and consumables over multiple passages to ensure accuracy. For cancer cell lines, STR profiling and mycoplasma testing are conducted regularly, while stem cell cultures are assessed for pluripotency and purity using imaging and flow cytometry. “Representative images of cell lines, captured using our EVOS imaging system,

In this episode of Life Sciences 360, we dive into the evolution of pharmaceutical and biotech manufacturing with our guest, Scott, a seasoned expert with nearly 30 years of experience working with industry giants like Novartis, Biogen, Thermo Fisher, and Merck. Scott shares insights on cell culture technology, mRNA vaccines, and the challenges and innovations in scaling biotech facilities. Discover the impact of collaboration and how organizations like the International Society for Pharmaceutical Engineering (ISPE) are transforming the landscape.Chapters :00:00 - Introduction to Vaccine Technologies00:14 - Importance of Collaboration in Pharma Manufacturing00:22 - The Role of Technology Ecosystems00:30 - Scott's Experience with ISPE00:46 - Motivation Behind Pharma & Biotech Careers01:09 - Welcoming Scott to Life Sciences 36001:19 - Scott's Background & Industry Experience01:45 - Integrating Technology in Pharmaceutical Facilities01:59 - Scott's Current Role & Unique Challenges02:18 - Interview Kickoff: Scott's Career Insights03:11 - The Evolution of Drug Manufacturing03:39 - Insights for Non-Pharma Audiences03:59 - Changes in Vaccine Manufacturing Over the Years04:40 - mRNA Technology and Its Impact05:05 - Encouraging Viewers to Subscribe05:59 - Driving Innovation in Manufacturing Facilities07:01 - Challenges in Scaling New Therapies08:17 - Overcoming Challenges in New Tech Implementation09:03 - The Role of Technology Vendors10:08 - Advancements in Manufacturing Technology11:02 - Evolution of Biotech Processes12:09 - Consulting in Cell and Gene Therapy13:02 - The Infancy of Cell and Gene Therapy13:23 - Introduction to SoulVentum14:01 - Separation from 3M and Vision for SoulVentum15:01 - Scott's Role at SoulVentum15:33 - Scott's Contributions to ISPE17:18 - Identifying Award-Winning Facilities18:39 - ISPE Facility of the Year Criteria20:18 - Global Reach of ISPE Submissions21:41 - Geographical Insights Post-Pandemic22:47 - The Role of ISPE in Pharma Collaboration23:31 - ISPE Communities of Practice24:47 - Forums & Conferences by ISPE26:19 - Local ISPE Chapters & Regional Support26:58 - Scott's Take on Industry Networking28:05 - The Importance of Professional Networks29:05 - Advice on Building a Career in Pharma30:21 - Scott's Mission in the Industry31:42 - Personal Impact of the Work in Pharma32:26 - Patient Stories and Their Motivational Impact33:22 - Closing Thoughts & How to Connect with Scott

Growing up in Eugene, Oregon, Lulu Tsui experienced a unique perspective on cannabis, where it was as common as backyard barbecues. This early exposure shaped her understanding of how cannabis perceptions could differ vastly from mainstream narratives. Lulu's journey led her to co-found On the Revel in 2016, a series of events challenging the status quo of New York City's cannabis industry. Her mission? To foster authentic connections and create a community where diversity and genuine conversation flourish beyond the typical trade show atmosphere. In this episode, host Carly Puch and Lulu dive into a fascinating conversation, exploring personal anecdotes and professional insights that reveal how early exposure and family acceptance can influence one's path in the cannabis sector. Lulu shares invaluable lessons learned along the way, including how humor and strategic media campaigns like "I'm High Right Now" are crucial in reducing stigma and shifting public attitudes toward cannabis. Carly and Lulu explore the importance of building diverse teams and prioritizing self-care in the dynamic field of cannabis. As we move through themes of personal growth, authenticity, and the importance of self-governance, Lulu reflects on how these principles guide her actions and decisions in both business and life. This episode offers juicy insights for anyone interested in the transformative potential of the cannabis industry or who just wants to level up in life, Lulu will inspire. Guest Bio: Lulu Tsui is the co-founder and chief experience officer at On The Revel, the parent company for a collection of curated educational and networking experiences that democratize information for those interested in the regulated cannabis industry. On The Revel events, known as Revelry, are conferences aimed at fostering an inclusive, collaborative, and flourishing cannabis sector. These regular in-person events along with On The Revel's Dope People online membership community, podcast, and virtual experiences, celebrate the diverse people that have been and are currently building the cannabis industry in the aim of developing its gold standard, with opportunities for all. Lulu is seasoned in Experience Design (XD) and User Experience (UX) with 15+ years of experience leading research, strategy, and design for enterprise software, Software as a Service (SaaS), mobile, and touchscreen technologies. Lulu applies her vast XD and UX expertise across verticals in the cannabis industry while championing ways to normalize and destigmatize cannabis and entheogens. Lulu has designed entire enterprise systems and introduced cross-platform mission-critical apps for clients Bloomberg LP, Mastercard, The Leukemia & Lymphoma Society, John Hopkins University, Roche, Thermo Fisher, Pearson, and McGraw-Hill. Lulu designed a software platform with Root Sciences aimed at supporting and standardizing operations and data for cannabis/hemp extraction, distillation, and post-processing. She also served as the principal experience designer for Chill, a cannabis e-commerce order and delivery platform. Along with On The Revel, Lulu serves as President of the Cannabis Media Council, an organization dedicated to destigmatizing and normalizing cannabis using the power of traditional media, and User Experience and Research Advisor at Oakland Hyphae, founders of the Oakland Psychedelic Conference and the Psilocybin Cup. https://ontherevel.com https://www.revelryny.com  Thanks for listening to another episode. Follow, review, and share to help Consciously Clueless grow! Connect with me: https://www.consciouslycarly.com/ Join the Consciously Clueless community on Patreon: https://www.patreon.com/consciouslycarly Connect on Instagram: https://www.instagram.com/consciously.carly/ Connect on Facebook: https://www.facebook.com/consciously.carly.blog Music by Matthew Baxley

Check out the New Bond account with an initial APY of 6.9%, only at https://public.com/csi We are discussing Twist Bioscience (TWST), a fascinating biotech company that helped revolutionize DNA synthesis -- but on silicon wafers. Of course Chip Stock Investor is interested! Nick and Kasey explore Twist's technology, market potential, and the competition they face from big players like Merck and Thermo Fisher. Plus, a closer look at the financials and future prospects of Twist Bioscience. However, stick around for a bonus analysis at the end on Analog Devices (ADI), how it might be powering Twist's DNA-on-silicon platform, and ADI might be the better investment choice long term. Don't miss out on this in-depth CSI episode! Join us on Discord with Semiconductor Insider: https://ko-fi.com/chipstockinvestor Supercharge your analysis with AI! Get 15% of your membership with our special link here: https://finchat.io/csi/

Compliance with environmental sustainability goals is no longer optional for medtech companies serving global healthcare markets. Thermo Fisher has made it a mission to be a leader in thought and actions in meeting Scope 1, 2 and 3 needs. Corporate VP and head of sustainability Meron Mathias explains the company's sustainability aims and methods, for itself and its customers, and stresses the importance of continuing to enhance patient care with innovative products at the same time.

Listen to the conversation as they discuss:How health equity is a key component of Thermo Fisher's core business.How Thermo Fisher leverages its capabilities and customer relationships to further its impact.Initiatives that improve health equity through accessibility to drug-resistant HIV testing, next-generation sequencing to diagnose lung and breast cancer in 30 underserved countries, increasing the accessibility to and diversity in clinical trials, and more.New programs in 2024.

Dr. Blackburne shares insights into:The challenges of recruiting women and minority groups for clinical trials, noting the logistical and societal barriers they face.Innovative solutions, such as telemedicine and flexible scheduling, to make trial participation more accessible. Recent advances in clinical research, including a groundbreaking preeclampsia test and contributions to COVID-19 vaccine trials, highlighting Thermo Fisher's pivotal role in these developments.

When you have a good thing going you often want it to last forever, but we know that can never happen. Life and the world around us are fluid, dynamic, and we're always finding the balance of fighting or harnessing entropy and inevitable change.As we encounter unexpected changes, we see them as chances to evaluate the foundations of our podcast's success while finding opportunities to evolve it and make it even better. Join us for a reflection of where we are, how we got here, and a sneak preview at what's to come. We're here to assure you, evolution is a good thing!

Steve Becker is committed to improving human health by unlocking the power of molecular diagnostics. In the world of medical devices and diagnostics, you might think the latter falls under the purview of the former, says Steve, yet: “from a regulatory standpoint, diagnostics is covered by a lot of the medical device rules.” Unlike medical devices like implants, however, “diagnostics is really the ability to measure your body, whether you're healthy or sick; and if you are sick, what's making you sick. Helping to uncover your health status and what you can do to improve is really the heart of diagnostics.”  In this episode, Steve shares the lasting lessons learned during his stints at Thermo Fisher, Quest Diagnostics, Agilent, and GE Healthcare, where he directed sales, global marketing, business development, and licensing. Learn how to navigate within a constantly changing healthcare business landscape, from the first steps toward launch to the regulatory requirements and cultural differences that can affect development, distribution, and product adoption.   Going to market on one's own is a big task, says Steve – find the right partners to mitigate the commercial regulatory tasks and technical risks. Ultimately, the company whose name is on the product assumes the liability – “they're the ones on the hook” – but relying on specialists along the way improves your chances of a streamlined launch.  During his tenure at Quest Diagnostics, the company built a “global diagnostics network,” pooling the capabilities, diagnostics insights, samples, testing and sharing of leading companies into one place. In the end, Quest brought the first Zika test to market, reliant upon colleagues.  In fact, choosing your initial target audiences can come into play even during development, as “diseases become more localized and companies are made for those markets,” Steve adds. Pay attention to “how to get paid for what you do,” your reimbursement strategy. In diagnostics, for example, ask yourself:  Is it going to measure what we say it's going to measure? (Analytic or clinical validity)  Can we do anything with the information? (Utility)  Interestingly, reimbursement can often become political; for example, in the US it's widely accepted that breast cancer can come with a genetic indicator (the BRCA gene) – and the patient can take prophylactic steps or opt for watchful waiting. In contrast, Steve says that:  In a single-payer system, if you were 49 you could take the [BRCA] test; if 50, no test. The calculation includes risk, quality of life, total cost – someone makes a decision, snapped the line, and that's where it landed.  Add to that differences stemming from culture and tradition, and it makes sense to work with local, in-country partners to navigate your go-to-market strategy, especially with regard to regulatory requirements.  To date, Steve says that European companies would often launch first domestically and then in the US because it was easier, but that's starting to change as the EU changes its regulatory stance.  Regulations are stricter now in Europe, with liability going as far back as the manufacturer – for translation quality, for example. Diagnostic tests are now treated more like a medical device, including review by regulatory bodies, etc. – it's a lot more work but it's a good thing.  Think globally but act locally, Steve adds. You may use the same assay (investigative procedure for qualitatively or quantitatively measuring the presence, amount, or functional activity of an element) as in the US but a local company can handle the technology, packaging, regulatory requirements, approvals, and clinical evidence and market under THEIR brand, with their own branding and local language. This happens consistently, across IV diagnostic companies – Abbott, Siemens, Roche, Thermo Fisher – and all of them have to treat each of their launches “locally,” working with in-country regulatory bodies to get approvals.  And vice versa: one of the first Covid tests distributed in the US was manufactured by a Korean company but marketed as a known American brand. In fact, working with companies around the world has interesting and complex effects on branding – “you'll get a multi-national brand but lose some efficiencies,” according to Steve.  In the end, Steve's advice is ever so simple: “You don't want to take risks in the healthcare world.”    Links:  LinkedIn: https://www.linkedin.com/in/stevebecker/    Connect with Wendy - https://www.linkedin.com/in/wendypease/  Music: Fiddle-De-Dee by Shane Ivers - https://www.silvermansound.com 

The fields of Cell and gene therapy are booming and poised to change the treatment and prevention of disease. These research areas require the transfer of genetic material to cells, and viral vectors are commonly used here. Specifically, adeno-associated virus (AAV) and lentiviral vectors (LVV) are vectors of choice. We're joined for this episode by MinGin Kim and Kimberly Gomez, both scientists at Thermo Fisher. With backgrounds and expertise in the areas of cell and gene therapy, they help explain what all the excitement is about and how AAV and LVV are used. We hear about some of the challenges associated with viral vector work and get to hear about how digital PCR (dPCR) and good assay design are helping overcome many of these challenges to enable research and the biopharmaceutical industry. As you might expect from Absolute Gene-ius, you also get to hear their respective career path journeys and some really interesting lab stories.Visit the Absolute Gene-ius page to learn more about the guests, the hosts, and the Applied Biosystems QuantStudio Absolute Q Digital PCR System. 

Would you ever consider leaving a secure and high-ranking position as a CEO at IBM Europe to join a startup as merely the 16th employee? Josh Geballe took that exact leap, moving away from the corporate security he knew to embrace the thrills and challenges of a startup, guided by what he describes as his "gut feeling."Josh's openness and straightforward approach are genuinely refreshing, yet it's clear that navigating such significant career shifts involves much more than instinct alone. It requires courage, foresight, and a willingness to face the unknown head-on.Since 2022, Josh has been a pivotal figure at Yale University, leading as the Managing Director of Yale Ventures (official website). In this role, he has been instrumental in spearheading the university's innovation ecosystem, catalyzing growth and collaboration across various disciplines.Reflecting on our days at Yale School of Management, I can't help but feel that having someone like Josh around back then would have been incredibly beneficial. His innovative spirit might have even lured me away from a traditional path in finance to explore the dynamic world of startups.In this podcast episode, Josh generously shares the wisdom gained from his two decades of varied experiences, which have been filled with both formidable challenges and substantial impacts. Here are some highlights from our conversation:As the COO during Connecticut's COVID-19 health response, Josh faced a public health crisis of unprecedented scale, the likes of which no MBA curriculum could ever anticipate or equip its students to handle. (press conf link)After spending over a decade at IBM in London, Josh made a decisive career shift to a startup in Connecticut that was later acquired by Thermo Fisher. This move exposed him to the intense realities of startup culture, where rapid growth can often be as daunting as it is exhilarating.At Yale, his current role involves driving the campus-wide innovation efforts. He elaborates on how he fosters a culture of innovation that supports the daily pursuits of students, faculty, and the broader university community, helping to translate abstract ideas into tangible, impactful realities.Tune in to this episode to gain insights from Josh's extensive experience with career transformations and his strategic approach to overcoming the obstacles that accompany change. It's sure to inspire and educate anyone interested in the intersections of innovation, leadership, and personal growth.Josh Geballe: https://www.linkedin.com/in/joshgeballe/ Vince Chan: https://www.linkedin.com/in/thevincechan/Chief Change Officer: Make Your Laws of Change.#1 Careers US on Apple Podcasts. Subscribe and be inspired!

Scott Wapner and the Investment Committee debate the state of stocks as the S&P tries to extend its record high. Plus, Bill Baruch is making some move in his portfolio, he calls in with the details. And later, we've got some calls of the day on Regeneron, Thermo Fisher, Darden Restaurants and more. Investment Committee Disclosures